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Trichomonas vaginalis is the most common sexually transmitted infection caused by a 
single known organism worldwide; and has been associated with an increased risk of HIV 
acquisition and transmission.  Despite its high prevalence in South Africa, limited 
information is available on the extent of T. vaginalis metronidazole resistance and 
genotypic variation in this setting.  We therefore tested the susceptibility of local T. 
vaginalis isolates against metronidazole and drugs prescribed in combination in the context 
of syndromic management of vaginal discharge syndrome.  Susceptibility testing of 40 
isolates demonstrated that metronidazole as well as some of the other drugs tested showed 
inhibiting effect on T. vaginalis.  We recommend that these drugs be tested for synergistic 
effect with metronidazole.  In a different set of 160 isolates the minimum inhibitory 
concentrations (MIC) of metronidazole ranged from 1.1 µg/ml to > 34.2 µg/ml (6.25 µM to 
> 200 µM) in the aerobic assay.  Interpretation of these MICs differed based on the 
different resistance breakpoints applied.  There was no correlation between MIC and 
treatment outcome in the subset of 56 patients that returned for follow-up.  The expected 
association between MIC and clinical outcome was only observed in one of eight patients 
with unsatisfactory treatment outcome.  This patient‘s isolate had the highest MIC.  In the 
remaining seven patients with unsatisfactory treatment outcome, no relation with the 
susceptibility test result was found. A possible reason for the poor correlation may be 
inadequate concentration of metronidazole at the site of infection.  In view of this, we 
assessed a self-administered and collected vaginal tampon specimen for the investigation 
of metronidazole concentration in the vagina of five healthy volunteers, using high 
performance liquid chromatography (HPLC).  Maximum values of metronidazole 
concentrations detected in both serum and vaginal fluid were obtained at two hours 
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following oral administration of 2 g of the drug. This method can be applied in future 
clinical studies to correlate treatment outcome and MICs with metronidazole concentration 
at the site of infection.  This may lead to the development of susceptibility assays and 
interpretation criteria that are better able to predict treatment outcome than the current 
methods.  Another reason for the poor correlation between treatment outcome and in vitro 
resistance may be early reinfection.  We used PCR-RFLP, targeting a 650-bp repeat region 
in the T. vaginalis genome, to genotype T. vaginalis isolates.  Four genotypes were found in 
100 T. vaginalis isolates using this method.  Both the vaginal secretion of metronidazole 
and the strain typing methodology needs to be further investigated before a comprehensive 
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Trichomonas vaginalis is the causative agent of trichomoniasis, which is the most 
common, treatable non-viral sexually transmitted infection (STI) (Muzny and Schwebke, 
2013).  According to the World Health Organisation (WHO) an estimated 276.4 million 
new cases of trichomoniasis occurred globally in 2008 (WHO, 2012).  Trichomoniasis 
prevalence rates in adults ranging from approximately 17% to 42% have been reported in 
eastern and southern Africa (Sturm et al., 1998; Watson-Jones et al., 2000; Buvé et al., 
2001; Apalata et al., 2014).  Various studies conducted in in South Africa reported very 
high T. vaginalis prevalence of approximately 15% to 42% (Sturm et al., 1998; Moodley et 
al., 2002a; Mlisana et al., 2012; Lewis et al., 2013; Apalata et al., 2014).  T. vaginalis 
infection has been associated with an increased risk of transmission of other STIs, 
including human immunodeficiency virus (HIV) (Buvé et al., 2001, McClelland et al., 
2007; Kissinger and Adamski, 2013).  Given the high prevalence of T. vaginalis, this 
association could be responsible for a substantial number of HIV infections globally 
(Sorvillo and Kerndt, 1998).    
 
Clinical manifestations of trichomoniasis in women range from asymptomatic carriage to 
profuse vaginal discharge, vulvar pruritis and dysuria.  In men trichomonas infection 
manifests as urethritis with dysuria and mild pruritis but is mainly asymptomatic (Thomason 
and Gelbart, 1989; Hammil, 1989; Paterson et al., 1998; Cudmore et al., 2004).  Some studies 
in men with urethritis report no association with the presence of T. vaginalis suggesting that 
symptomatology may be of short duration and self-limiting (Sturm et al, 2004).  Pregnant 
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women infected with T. vaginalis are predisposed to premature labour, premature rupture of 
membranes and low-birth-weight infants (Petrin et al., 1998).     
 
T. vaginalis can be detected in vaginal, prostatic and urethral secretions as well as in semen 
and urine.  For long culture was considered the most reliable diagnostic method with a 
reported sensitivity of >90% for detecting T. vaginalis in some studies (Philip et al., 1987; 
Beverly et al., 1999), it requires complex media and is time-consuming.  Various nucleic acid-
based methods have since been developed to improve the specificity but in particular the 
sensitivity of the laboratory diagnosis (Shaio et al., 1997; Paterson et al., 1998; Nye et al., 
2009; Andrea et al., 2011; Schwebke et al., 2011).  However, culture is still essential to allow 
for susceptibility testing. 
 
The only drugs proven to be effective against trichomoniasis are the 5-nitroimidazoles, 
specifically metronidazole and tinidazole (Secor, 2012).   Metronidazole is for many years the 
principle drug used to treat trichomoniasis (Lofmark et al., 2010).  The standard treatment is 
given orally in a single 2 g dose (Centers for Disease Control and Prevention [CDC], 2010).   
Most isolates of T. vaginalis are highly susceptible to metronidazole but resistance has been 
reported (Thurner and Meingassner, 1978; Kulda et al., 1982; Muller et al., 1988; Dunne et 
al., 2003; Schwebke and Barrientes, 2006; Upcroft et al., 2009; Bosserman et al., 2011; 
Kirkcaldy et al., 2012; Rukasha et al., 2013). Several susceptibility testing methods for 
metronidazole have been described (Thurner and Meingassner, 1978; Ralph et al., 1983; 
Upcroft and Upcroft, 2001a), however the results obtained may not always correlate with 
response to treatment (Muller et al., 1988; Schwebke and Barrientes, 2006; Bosserman et al., 




Treatment failure in patients infected with T. vaginalis may be due to early reinfection, non-
adherence to treatment, poor absorption of the drug, failure of the drug to reach the site of 
infection or infection with a drug resistant strain (Kane et al., 1961; Petrin et al., 1998).  Since 
trichomoniasis is a localised infection and metronidazole is administered systemically, the 
reasons for treatment failure may be better understood if the concentration of the drug at the 
site of infection is known and if reinfection between initiation of treatment and follow-up 
investigations could be excluded.  
 
Several studies have described the use of high performance liquid chromatography (HPLC) to 
determine the metronidazole concentration in biological fluids (Galmier et al., 1998; 
Mustapha et al., 2006; Emami et al., 2006).  Many of these studies reported on metronidazole 
levels in plasma, serum or urine.  Only a few studies investigated metronidazole levels in 
vaginal secretions (Manthei et al., 1969 cited by Larsen et al., 1986; Davis et al., 1984; 
Larsen et al., 1986; Robertson et al., 1988).  
 
To exclude reinfection, a reproducible and discriminatory typing method is required. Due to 
the worldwide high prevalence of trichomoniasis, there is a need to understand the genetic 
diversity of the organism that causes it (Cornelius et al., 2012). This has led to the 
development of an array of typing methods that aimed to characterize T. vaginalis isolates.  
Molecular typing methods for T. vaginalis previously reported include, but are not limited to, 
pulsed-field gel electrophoresis (PFGE), restriction fragment length polymorphism (RFLP) 
analysis, random amplified polymorphic DNA (RAPD) analysis, and multilocus sequence 
(MLST) typing, (Upcroft et al., 2006a; Crucitti et al., 2008; Valadkhani et al., 2011; 
Cornelius et al., 2012; Meade and Carlton, 2013).  Although these various methods have 
been used to characterize T. vaginalis, there is no “gold standard” method for typing T. 
vaginalis isolates (Cornelius et al., 2012).   
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Very few studies describing strain typing or antimicrobial susceptibility testing of South 
African isolates of T. vaginalis have been reported (Upcroft et al., 2006a; Upcroft et al., 
2006b; Kock et al., 2013; Rukasha et al., 2013).  Furthermore, the degree of metronidazole 
resistance in Kwazulu-Natal, the province of South Africa with the largest population, has not 
been previously investigated.  In view of this the present study was designed, using isolates 
from selected cohorts of individuals from Kwazulu-Natal, to perform antimicrobial 
susceptibility testing; and to develop a molecular typing method to characterize T. vaginalis 
isolates.  In addition, due to the limited information currently available on metronidazole 
concentrations in the vagina after standard oral therapy, we developed a method for 
determination of metronidazole levels in vaginal fluid. 
 
1.2 AIMS OF THIS STUDY 
 
• To perform antimicrobial susceptibility testing using the broth macro-dilution 
method against syndromic management drugs; and to determine the susceptibility 
of T. vaginalis isolates to metronidazole under both aerobic and anaerobic 
conditions using the broth micro-dilution method. 
• To develop a method for determination of metronidazole concentration in vaginal 
secretions using HPLC. 
• To use PCR-RFLP genotyping to characterize T. vaginalis isolates  
 
Accordingly, this thesis has been divided into three components: antimicrobial 
susceptibility testing of T. vaginalis, the development of a methodology using HPLC to 
detect metronidazole concentration in vaginal secretions and PCR-RFLP genotyping to 





REVIEW OF LITERATURE 
 




Trichomonas vaginalis is the cause trichomoniasis which is one of the most common sexually 
transmitted infections (Bachmann et al., 2011; Hillier, 2013).  This protozoan was first observed 
and described in 1836 by a French physician, Alfred Donné, who considered it an etiologic 
agent of vaginitis. In 1896, Dock cited by Thomason and Gelbart, 1989, questioned whether the 
protozoan was a pathogen, since males and females harbouring the organism were frequently 
asymptomatic.  It was finally demonstrated in 1916 by Hoehne, that by eradicating the parasite 
in symptomatic patients, one would eliminate the resultant vaginitis.  The organism was again 
ignored until Johnson et al., 1943 cited by Thomason and Gelbart, 1989, developed a culture 
medium that allowed study of the organism in an axenic environment, free of bacteria and fungi. 
 This cysteine-peptone-liver extract-maltose medium later evolved into Kupferberg's medium, 
developed in 1948 (Gelbart et al., 1990).  Diamond’s trypticase-yeast-maltose (TYM) medium 
was developed in 1957 (Diamond, 1957 cited by Gelbart et al., 1990).  The development of a 
culture medium made it possible to test the protozoan for antibiotic susceptibility.  Thus in 1959, 
Cosar and Julou cited by Thomason and Gelbart, 1989, discovered that metronidazole kills the 
organism. 
 
2.1.2 Morphology and structure  
 
T. vaginalis is a unicellular, flagellated protozoan which resides extracellularly in the lower 
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genitourinary tract of human beings, it’s only natural host (Schwebke and Burgess, 2004).  T. 
vaginalis cells vary in size and shape (Petrin et al., 1998).  The average size is approximately 10 
by 7 µm and it generally appears pyriform or ovoid (Petrin et al., 1998).  The shape of the 
organism is more uniform in axenic culture (Figure 2.1[A]), but it appears in an amoeboid form 
when attached to vaginal epithelial cells (Figure 2.1 [B and C]) (Petrin et al., 1998). 
 
 
Figure 2.1: (A) T. vaginalis in broth culture with visible axostyle, undulating membrane and 
flagella.  (B) T. vaginalis on the vaginal epithelial cell surface before amoeboid transformation (C) 
Amoeboid form of T. vaginalis in cell culture using vaginal epithelial cells (Arroyo et al., 1993 cited 
by Petrin et al., 1998) 
 
The organism has five flagella. Four flagella are situated at its anterior pole while the fifth is, 
incorporated within the undulating membrane which extends along the body of the parasite 
(Petrin et al., 1998) (Figure 2.1[A]).  The flagella and undulating membrane give this parasite a 
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characteristic jerky movement as well as rapid motility (Petrin et al., 1998).  T. vaginalis can 
gather and internalize the flagella under unfavourable growth conditions (Petrin et al., 1998).  
The cytoplasmic costa is located beneath the undulating membrane.  The axostyle, a rigid 
structure runs its entire length, protrudes from the posterior pole and bisects the organism 
longitudinally (Petrin et al., 1998; Schwebke and Burgess, 2004).  Similar to eukaryotic cells, 
the nucleus which is located towards the anterior portion of the organism is enclosed by a 
porous nuclear envelope (Petrin et al., 1998).  A Golgi apparatus resembling a parabasal body is 
situated in the cytoplasm adjacent to the nucleus. Multiple granular organelles called 
hydrogenosomes (Benchimol et al., 1996), which are unique to trichomonads, are found along 
the axostyle and costa.  Hydrogenosomes are involved in the organisms’s metabolic pathways 
(Dunne et al., 2003).  These organelles generate hydrogen by converting pyruvate to acetate, 
carbon dioxide, and hydrogen. The reduced hydrogenosomal protein, ferredoxin, may be 
involved in the maintenance of an anaerobic environment within the intracellular space 
(Cudmore et al., 2004).   
 
Whether T. vaginalis, like most pathogenic protozoa, has a life cycle has not been resolved 
(Sood and Kapil, 2008).  It is generally accepted that the organism exists only in the trophozoite 
form and is unable to form cysts (Petrin et al., 1998).  The absence of a phase that is 
environmentally resistant is thought to explain its mode of transmission by close bodily contact. 
 Some reports have however suggested that the organism may assume a pseudocyst form under 
unfavourable environmental conditions (Pereira-Neves et al., 2003). The organism reproduces 






2.1.3 Metabolism and Growth 
 
T. vaginalis have hydrogenosomes which play a similar role as mitochondria in aerobically 
metabolising eukaryotic cells (Lindmark and Muller, 1973 cited by Bradley et al., 1997).  These 
organelles produce hydrogen, process carbohydrates (Petrin et al., 1998), metabolize pyruvate 
and produce adenosine triphosphate (ATP) through substrate-level phosphorylation (Bradley et 
al., 1997).  Three proteins: pyruvate:ferredoxin oxidoreductase, ferredoxin and iron-only [Fe]-
hydrogenase, are sequentially involved in the metabolism of pyruvate (Gehrig and Efferth, 
2009).  T. vaginalis does not have metabolic pathways required for the synthesis of sterols and 
fatty acids (Beach et al., 1990).  Therefore, the organism has mechanisms to facilitate the uptake 
of plasma proteins and lipoproteins necessary for its growth (Peterson and Alderete, 1982; 
Peterson and Alderete, 1984). 
 
T. vaginalis is unable to synthesize many macromolecules, such as purines, pyrimidines and 
many lipids. It therefore needs another organism that is able to provide these molecules and is 
thus an obligate parasite (Petrin et al., 1998).  T. vaginalis obtains these substances from vaginal 
secretions or via phagocytosis of bacteria, yeasts, and erythrocytes (Heine and McGregor, 
1993).  Culture media for T. vaginalis should therefore include all essential macromolecules, 
vitamins and minerals (Petrin et al., 1998).  The most widely used culture medium for T. 
vaginalis is Diamonds TYM medium (Clark and Diamond, 2002) which contains horse serum 
as a main source of organic substances.  Optimal growth of T. vaginalis occurs under anaerobic 






2.1.4 Trichomonas vaginalis Virus (TVV) 
 
 
The Trichomonas vaginalis double stranded RNA virus (TVV) was first identified by Wang 
and Wang in 1985.  (Wang and Wang, 1985a).  The size of the viral RNA strand has been 
reported to vary between 4.3 and 5.5 kb (Wang and Wang, 1985b; Khoshnan and Alderete, 
1993).  T. vaginalis isolates can be infected with more than one strain of TVV concurrently 
(Benchimol et al., 2002).  Goodman and colleagues found two T. vaginalis isolates to be 
concurrently infected by four strains of TVV (Goodman et al., 2011).  TVV was shown to be 
present in T. vaginalis isolates obtained from various different countries including South 
Africa (Snipes et al., 2000; Weber et al., 2003; Fraga et al., 2005; Kim et al., 2007; 
Goodman et al., 2011; Heidary et al., 2013).  TVV was detected in 59 of the 72 (81.9%) 
isolates collected from hospitals in Ga-Rankuwa and Cape Town, SA (Weber et al., 2003).  
Although the biological functions of the TVV genetic information is not known (Goodman et 
al., 2011), it was previously suggested that this virus may be associated with the expression 
of P270, a highly immunogenic T. vaginalis surface protein (Khoshnan and Alderete 1994; 
Kim et al., 2007) and with the expression of cysteine proteinases (Provenzano et al., 1997). 
T. vaginalis isolates have been divided into two types based on the presence or absence of the 
TVV: isolates not infected with TVV are designated Type I and those infected with TVV are 




The total number of new cases of T. vaginalis in 2008 in adults between the ages of 15 and 49 
was estimated to be 276.4 million (WHO, 2012). There is currently however very limited 
population based data to inform these global estimates (Poole and McClelland, 2013).  T. 
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vaginalis has a worldwide distribution and has been found in all age, racial and socioeconomic 
groups (Sood and Kapil, 2008; Leon et al., 2009; Madhivanan et al., 2009; Napierala et al., 
2010; Apalata et al., 2014).  Both men and women may be infected, although the prevalence is 
higher in women (Eshete et al., 2013).  However, this may be an underestimation since most 
infections in male are asymptomatic suggesting the presence of low numbers of organisms that 
easily escape detection (Hobbs et al., 2006). The prevalence of T. vaginalis has been shown to 
increase with age in males and females (Joyner et al., 2000; Ginocchio et al., 2012). Older 
individuals may not consider themselves at risk and may therefore engage more frequently in 
unprotected sex (Olivi et al., 2008), which could then lead to acquisition of STIs. Another 
explanation may be that repeated infection leads to milder symptomatology and consequently 
delayed or no treatment. 
 
Trichomoniasis has been associated with a 1.5 (1.5–3.0) times increased risk of HIV acquisition 
(Lazenby, 2011). Several recent studies have reported this epidemiologic synergy between T. 
vaginalis and HIV (McClelland et al., 2007; Shafir et al., 2009; Napierala et al., 2010).  The 
actual burden of the disease in South Africa, where HIV is also endemic, is unknown. Available 
prevalence data are from studies carried out in selected populations that may not be 
representative of the total population.  In a study by Moodley et al., 2003, prevalence of T. 
vaginalis in South African women attending a reproductive health clinic was 29%.  More 
recently in South Africa, there were reports of a prevalence of 6.1% in men and 23.6% in 
women attending a primary health care clinic in Johannesburg (Lewis et al., 2013). In Durban a 
prevalence of 20.3% was found amongst a cohort of high-risk HIV-negative female sex workers 
(Mlisana et al., 2012), and in approximately 16% of 198 female patients attending a primary 
health care facility with vaginal discharge syndrome (Apalata et al., 2014).   
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2.3 TRANSMISSION  
 
The pathogen is transmitted during sexual intercourse. The organism inhabits the genitourinary 
tract and thrives on the surface of squamous epithelial cells lining the vagina, urethra and Skene 
glands in women and in the seminal vesicles, urethra and prostate gland in men.  It can also be 
found in the preputial sac of uncircumcised males (Thomason and Gelbart, 1989).  The 
incubation period in women, has been reported to vary from 4 to 28 days in about 50% of 
infected individuals.  When assessed within 48 hours after sexual contact with an infected 
female, it was shown that 70% of males carried the organism (Thomason and Gelbart, 1989).  
Non-sexual transmission of T. vaginalis is theoretically possible.  One study reported a high 
prevalence of T. vaginalis in virgins and the authors suggested that the organism could have 
been transmitted through shared bathing water and poor hygiene (Crucitti et al., 2011).  Given 
that the organism is so site-specific, non-sexual transmission is believed to be a rare occurrence 
(Thomason and Gelbart, 1989).   
 
2.4 CLINICAL MANIFESTATIONS  
 
T. vaginalis colonises the squamous epithelium of the female genital tract, however it can be 
recovered from the urethra, and has been found in the internal genitalia of female as well (Petrin 
et al., 1998; Moodley et al., 2002b).  Symptomatic women may present with signs of profuse 
vaginal discharge, malodour, labial edema, erythema and/or vulvar pruritis and with symptoms 
of dysuria, and/or dyspareunia (Petrin et al., 1998). More than half of the symptomatic women 
present with vaginal discharge.  The type of discharge depends on the presence of associated 
bacteria.  There is a strong association with trichomoniasis and bacterial vaginosis because T. 
vaginalis creates an anaerobic environment and an increase in vaginal pH, thereby changing the 
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vaginal flora (Thomason et al., 1988).  Less than 10% of symptomatic women present with 
classic green, frothy, foul-smelling discharge and, punctate haemorrhagic lesions on the cervix 
(strawberry cervix) are detected in approximately 2% of infected women (Petrin et al., 1998).  It 
has been reported that symptoms often are first noticed or are exacerbated at menstruation or 
after sexual intercourse (Grist et al., 1987).  Adverse pregnancy outcomes such as premature 
rupture of membranes and preterm birth have been associated with T. vaginalis infection (Cotch 
et al., 1997).  It has been shown in previous studies that 25-50% of women with T. vaginalis are 
asymptomatic (Schwebke and Burgess, 2004; Seña et al., 2007; Piperaki et al., 2010) 
 
Trichmoniasis is asymptomatic in 40% to 75% of men (Schwebke and Hook, 2003; Seña et al., 
2007) and its role in male urethritis syndrome remains obscure (Sturm et al., 2004).  
Symptomatic men usually complain of urethral discharge, dysuria, mild pruritis, or burning 
directly after sexual intercourse (Thomason and Gelbart, 1989).  The lower numbers of 
organisms found in males has been associated with the presence of zinc in prostatic fluid 
(Kriege and Rein, 1982).  Zinc has antitrichomonal activity in vitro and it has therefore been 




Several methods including microscopy, culture, antigen detection tests and nucleic acid 
amplification tests have been used for diagnosis of trichomoniasis (Hobbs and Seña, 2013).  The 
organism can be detected in vaginal, urethral and prostatic secretions as well as in semen and 
urine.  A commonly applied diagnostic method for diagnosis of T vaginalis infection in women 
is microscopic examination of a wet mount preparation of vaginal secretions mixed with normal 
saline (Hobbs and Seña, 2013).  Observation of the pear-shaped trichomonads with their 
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distinctive motility is considered highly specific.  However when compared to nucleic acid 
amplification tests, the sensitivity of microscopy ranges from 44% to 68% (Huppert et al., 2007; 
Patil et al., 2012).  Microscopic examination of male urethral specimens or urine sediment has 
low sensitivity for detection of T vaginalis infection in men due to the presence of fewer 
organisms (Hobbs et al., 2006).   
 
Culture is more sensitive than direct microscopic examination (Hobbs and Seña, 2013).  
Cultures of vaginal specimens from women with trichomoniasis are usually positive after three 
days of inoculation but it can take up till seven days before growth is detected. Time-to-
positivity depends on the concentration of organisms in the specimen. Therefore, delayed 
diagnosis by culture is seen particularly in asymptomatic women and in men (Garber, 2005).  
Cultures must be microscopically examined daily for five to seven days before being regarded 
as negative (Hobbs et al., 2006).  To simplify diagnosis by culture, the InPouch system (BioMed 
Diagnostics, USA) was developed (Borchardt and Smith, 1991).    The system consists of a 
flexible oxygen impenetrable plastic pouch which contains the culture medium. The contents 
can be microscopically examined daily without opening the pouch (Borchardt and Smith, 
1991).   
 
More recently rapid, non-culture diagnostic tests that detect T vaginalis antigens or nucleic acids 
were developed (Hobbs and Seña, 2013).  The commercially available antigen detection tests 
include the OSOM Trichomonas Rapid Test (Sekisui Diagnostics, California, USA) and the TV 
latex agglutination test (Kalon Biological, Surrey, UK).  Affirm VPIII (Becton Dickinson, 
Maryland, USA) detects nucleic acid by probe hybridisation without amplification. This test 





As for many infectious diseases, nucleic acid amplification tests (NAATs) now provide highly 
sensitive tools for diagnosis of T. vaginalis infection.  NAATs find their origin in polymerase 
chain reaction (PCR) technology and include classic PCR, transcription-mediated amplification 
(TMA) and other technical variations that amplify specific trichomonal DNA or RNA target 
sequences (Hobbs and Seña, 2013). Because these methods increase the copy numbers of the 
diagnostic marker, the analytical sensitivity of NAATs is higher than that of microscopy, 
culture, antigen detection or nucleic acid probe assays (Hobbs and Seña, 2013), which all 
depend on the concentration of organisms in the specimens. The TMA-based APTIMA® T. 
vaginalis assay (Hologic Gen-Probe Inc, California, USA) received the EU CE mark and US 
Food and Drug Administration (FDA) clearance for in vitro detection of T. vaginalis in 
specimens from women (Schwebke et al., 2011).  T. vaginalis NAAT sensitivities range from 
76% to 100% (Nye et al., 2009, Andrea and Chapin, 2011, Schwebke et al., 2011).  Although 
NAATs may eventually replace less sensitive tests for diagnosis of T vaginalis infection, culture 
will continue to be important in cases of persistent infection or suspected treatment failure for 





The only drugs proven to be effective for treatment of T. vaginalis are the 5-nitroimidazoles of 
which metronidazole and tinidazole have proven efficacy in clinical trials (Robertson et al., 
1988; Forna and Gülmezoglu, 2007).  The single dose metronidazole regimen was first used in 
1971 (Csonka, 1971 cited by Gabriel et al., 1981).  Subsequently, other studies were conducted 
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to demonstrate efficacy of the 2 g oral dose of metronidazole (Thin et al., 1979; Gabriel et al., 
1981).  This treatment regimen with a 2 g single dose of metronidazole is usually uncomplicated 
and is well tolerated (Samuelson, 1999). A single 2 g oral dose of either metronidazole or 
tinidazole is currently used for treatment of trichomoniasis in both men and women (Muzny and 
Schwebke, 2013).  It is recommended that both partners are treated (Centers for Disease Control 
[CDC], 2010), even if one of them is asymptomatic.  Despite reports on teratogenicity in 
animals (Chacko and Bhide, 1986), single dose oral metronidazole has been proven to be safe in 
pregnancy, including the first trimester (Burtin et al., 1995).  
 
According to the CDC, individuals can be treated with 500 mg of metronidazole twice daily for 
seven days if treatment failure occurs with a 2 g dose of metronidazole, and reinfection has been 
excluded (CDC, 2010).   Treatment with a 2 g oral dose of metronidazole or tinidazole once 
daily for five days should be considered in the event that this regimen fails (CDC, 2010).  
 
A 7-day regimen of metronidazole 500 mg orally twice daily may be preferred for the treatment 
of T vaginalis in HIV-infected women (Muzny and Schwebke, 2013).  A recent study showed 
that single-dose therapy with metronidazole was not as effective as the 7-day regimen in a 
cohort of HIV positive women (Kissinger et al., 2010).   On the contrary a study conducted 
among women attending a primary healthcare clinic in SA showed that microbiologic cure rates 
for T. vaginalis were independent of HIV status after 8 to 10 days following treatment with a 2 g 
stat dose of metronidazole (Moodley et al., 2003).  A similar finding was reported in a recent 
prospective cohort study (Balkus et al., 2013). 
 
Treatment options are still limited in patients with treatment resistance and/or nitroimidazole 
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allergy.  The use of numerous alternative chemotherapeutic agents has been reported (Cedillo-
Rivera et al., 2002, Camuzat-Dedenis et al., 2001; Bouma et al., 1998), however there is 
currently no proven effective alternative ((Munzy and Schwebke, 2013). 
 
 
2.7 RESISTANCE TO 5-NITROIMIDAZOLES 
 
Although metronidazole is the drug of choice for treatment of trichomoniasis, resistant T. 
vaginalis isolates have been isolated (Thurner and Meingassner, 1978; Muller et al., 1980; 
Dunne et al., 2003). The reported prevalence of metronidazole resistance varies from 2 to 17% 
in women (Schmid et al., 2001; Schwebke and Barrientes, 2006; Kissinger et al., 2008; Upcroft 
et al., 2009; Krashin et al., 2010; Kirkaldy et al., 2012; Rukasha et al., 2013).  In vitro drug 
resistance amongst T. vaginalis is ubiquitous (Meri et al., 2000; Perez et al., 2001; Lo et al., 
2002; Dunne et al. 2003; Upcroft et al., 2009; Bosserman et al., 2011; Kirkaldy et al., 2012; 
Rukasha et al., 2013) however accurate data on the magnitude of clinically resistant 
trichomoniasis are not available (Sood and Kapil, 2008).  It is also important to note that it is 
difficult to differentiate between reinfection and resistance (Van Der Pol et al., 2005).  So far, 
understanding of the exact mechanism of resistance in T. vaginalis isolates to the 5-
nitroimidazoles is limited (Secor, 2012). 
 
Organisms isolated from patients with treatment failure usually display increased minimal 
inhibitory concentrations (MIC) of metronidazole in susceptibility assays conducted aerobically 
(Kulda et al., 1982; Lossick et al., 1986; Muller et al., 1988; Rasoloson et al., 2002; Dunne et 




2.7.1 In vitro metronidazole resistance  
 
Metronidazole penetrates T. vaginalis by means of passive diffusion and results in the release of 
cytotoxic nitro anion radicals via anaerobic reduction (Sood and Kapil, 2008).  Drug activation 
occurs in the hydrogenosome where the drug is reduced by pyruvate: ferredoxin oxidoreductase 
(PFOR). Since the concentration difference of the non-active unprocessed molecule drives the 
diffusion process, the activation of the drug facilitates the entry of more drug into the organism 
and the accumulation of cytotoxic radicals (Land and Johnson, 1999; Sood and Kapil, 2008).   
Leitsch and colleagues described an alternate pathway for 5-nitroimidazole drug activation 
(Leitsch et al., 2009).  They suggested that the nitroreductase activity of the flavin dependent 
enzyme thioredoxin reductase activates the 5-nitroimidazole drugs, including metronidazole, 
to their toxic form in the T. vaginalis cytoplasm (Leitsch et al., 2009).    
 
Metronidazole MICs obtained under aerobic and anaerobic incubation conditions differ (Kulda, 
1999; Rasoloson et al., 2002). MICs have been shown to be higher in susceptibility assays 
carried out aerobically compared to those carried out anaerobically (Upcroft and Upcroft, 2001a; 
Upcroft and Upcroft, 2001b). This is due to various mechanisms of drug action (Dunne et al., 
2003; Gehrig and Efferth, 2009).   
 
Aerobic resistance 
This type of resistance is characterised by impaired oxygen scavenging processes (Rasoloson et 
al., 2001) and represents the earliest stage in resistance (Dunne et al., 2003; Gehrig and Efferth, 
2009).  This process results in an increased oxygen concentration inside the organism impairing 




Anaerobic Resistance  
It has been reported that clinical isolates also exhibit resistance under anaerobic conditions 
(Upcroft and Upcroft, 2001b; Dunne et al., 2003; Voolmann and Boreham, 1993 cited by 
Cudmore et al., 2004).  Resistance under anaerobic conditions can be developed in vitro by 
continuously exposing the organisms to increasing concentrations of metronidazole (Dunne et 
al., 2003).  This type of resistance is independent of oxygen scavenging (Gehrig and Efferth, 
2009) and is associated with decreased expression levels of the hydrogenosomal enzymes 
involved in drug activation, i.e. PFOR, malic enzyme, NADH:ferredoxin oxidoreductase 
(NADH:FOR), ferrodoxin and FE-hydrogenase (Rasoloson et al., 2002; Gehrig and Efferth, 
2009).    Ferredoxin gene mutations were also detected in clinical isolates of T. vaginalis 
(Heidari et al., 2013).  It was however concluded that additional in vitro and in vivo studies are 
required to determine the association between ferredoxin gene mutation and resistance to 
metronidazole in clinical isolates of T.vaginalis.  
 
2.8 ANTIBIOTIC SUSCEPTIBILITY TESTING 
 
Antimicrobial susceptibility testing is done in order to assess susceptibility to antimicrobial 
agents, and to detect possible drug resistance in organisms (Jorgensen and Ferraro, 2009).  It 
provides information to prescribers on the choice of appropriate antimicrobial drugs for therapy 
or prophylaxis of infections in specific patients, or to aid in antimicrobial policy formulation 
(MacGowan and Wise, 2001).  Data generated from susceptibility testing may also be used to 
track the occurrence and prevalence of antimicrobial resistance within specific geographical 
areas (Macgowan and Wise, 2001).  Commonly used susceptibility testing methods include 
broth dilution tests, agar dilution tests, antimicrobial gradient diffusion, disk diffusion tests, and 
automated instrument systems (Jorgensen and Ferraro, 2009).   
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The broth dilution tests are used as susceptibility testing methods for T. vaginalis. The broth 
macro-dilution method is one of the earliest antimicrobial susceptibility testing methods that 
were developed (Ericsson and Sherris, 1971).  This involves preparing two-fold dilutions of 
antibiotics (e.g. 16, 8, 4, 2, and 1 µg/ml) in a liquid growth medium dispensed into test tubes 
(Cates, 1999).  The tubes containing the antibiotic are inoculated with a standardised 
suspension of organism depending on the type organism tested.  Following incubation at the 
prescribed time and temperature the tubes are examined for visible growth of the organism 
(Andrews, 2001).  The accuracy of this method is considered to be ± one two-fold 
concentration due mainly to the practice of manually preparing serial dilutions of the antibiotics 
(Balows, 1972 cited by Jorgensen and Ferraro, 2009).   
 
Broth dilution testing became more popular and practical after the method was miniaturized by 
use of small, disposable, plastic “micro-dilution” trays (Jorgensen and Ferraro, 2009).  A 
standard 96-well tray contains a volume of 200 µl per well and allows approximately 8 
antibiotics to be tested in a range of 10 two-fold dilutions (two wells in each row are used for 
controls) (Jorgensen and Turnidge, 2007). Micro-dilution allows automation.  Antimicrobial 
test panels are prepared using dispensing instruments, e.g. multi-channel pipettes that aliquot 
exact volumes of broth containing pre-weighed and diluted antibiotics into the individual wells 
of the tray.  The panels are similarly inoculated with the standardised suspension of organisms. 
 Many trays can be prepared from a single master set of dilutions (Jorgensen and Ferraro, 
2009).  Following incubation each of the wells is inspected for growth using a manual or 





2.8.1. Breakpoints and interpretation of in vitro susceptibility tests 
 
Drug susceptibility of a microbe may be assessed by measuring the minimal inhibitory 
concentration (MIC) and/or minimum lethal concentration (MLC) of the drug for the organism 
being tested (Mayers, 2009).  The MIC is the lowest concentration of an antimicrobial that 
prevents multiplication of the organism (Andrews, 2001).  The MLC is the lowest 
concentration of drug at which all organisms are killed (i.e. no growth on subculture) (Mayers, 
2009). MICs are considered the “gold standard” for determining the susceptibility of organisms 
to antimicrobials (Andrews, 2001).  Diagnostic laboratories use MICs to confirm resistance and 
to provide a definitive answer when a borderline result is obtained by other testing methods 
(Andrews, 2001).  The range of antibiotic concentrations used for determining MICs is 
universally accepted to be in doubling dilution steps up and down from 1 µg/ml.  
 
In susceptibility testing a breakpoint is defined as “a discriminating concentration used in the 
interpretation of results of susceptibility testing to define isolates as susceptible, intermediate or 
resistant” (MacGowan and Wise, 2001).  The rationale for determining a breakpoint is based on 
the assumption that an organism defined as “susceptible” should respond to the standard 
antibiotic dose, a “resistant” organism should not respond, and an “intermediate” one may or 
may not respond to standard doses, yet would have an increased chance to respond to a greater 
dose if the infection is at a site where the antimicrobial is actively concentrated (MacGowan 
and Wise, 2001).  However this information regarding concentration of the drug at the site of 
infection is often not known (MacGowan and Wise, 2001).  For most antimicrobial drugs two 
breakpoints are recognised. The breakpoint for resistance determines the value above which 
test organisms are labelled “resistant” while the breakpoint for susceptibility represents the 
value below which these are “susceptible”. In between these two breakpoints is the 
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intermediate zone.  
 
Ideally breakpoints should be determined by comparing response to treatment to a drug with 
the MIC values for that same drug. However, reports on such studies are rare (Moodley et al., 
2002c).  There are two main reasons for that. Firstly, such studies need to be done in a cohort 
that includes patients with infections caused by susceptible as well resistant organisms.  
However, treating patients with an antimicrobial drug to which the causative organism is 
resistant is unethical.  The second problem is that such studies need to be done in patients with 
the same disease caused by the same organism while many infections can have different 
aetiology.  Furthermore, since the patient’s clinical condition at the initiation of treatment 
influences outcome, patients need to be stratified according to severity of disease.  For these 
reasons, breakpoints used are established by consensus and are largely extrapolations based on 
blood concentrations achieved in volunteers combined with poorly controlled clinical 
observations. 
 
As for most infections, it has also been reported that some patients with trichomoniasis infected 
with an in vitro “resistant” organism respond well to standard metronidazole therapy, and 
others with a “susceptible” organism fail to respond (Schwebke and Barrientes, 2006; 
Bosserman et al., 2011).  There is no standardised in vitro assay (Mayers, 2009) or no agreed 
breakpoints available for susceptibility testing of T. vaginalis.  Given the different types of 
susceptibility assays used, and mixed reporting of either MIC or MLC values, direct 





2.8.2 Antimicrobial susceptibility testing of T. vaginalis 
 
Broth macro-dilution and broth micro-dilution are the methods commonly used for 
antimicrobial susceptibility testing of T. vaginalis (Upcroft and Upcroft, 2001a).  Several 
studies reported on in vitro susceptibility to metronidazole (Muller et al., 1988; Meri et al., 
2000; Snipes et al., 2000; Perez et al., 2000; Stiles et al., 2000; Upcroft and Upcroft, 2001a; 
Crowell et al., 2003; Schwebke and Barrientes, 2006; Kissinger et al., 2008; Upcroft et al., 
2009; Bosserman et al., 2011; Kirkaldy et al., 2012; Rukasha et al., 2013).  These studies used 
a variety of different MIC or MLC breakpoints to define “susceptible”, “intermediate” and 
“resistant” isolates.  Upcroft and Upcroft (2001a) developed a modified broth micro-dilution 
method, and recommended MIC breakpoints based on tests performed on T. vaginalis isolates 
from known responders and non-responders (See Chapter 4, Table 4.10). The authors suggest 
that this method with accompanying breakpoints may have the potential to be used widely for 
the determination of antimicrobial susceptibility in T. vaginalis.  (Upcroft and Upcroft, 2001a). 
 This needs to be verified by means of a prospective study that compares clinical outcome with 
the MIC of the organism isolated from the same patient. 
 
Several studies have described the relationship between susceptibility of T. vaginalis to 
metronidazole and treatment outcome (Muller et al., 1988; Schwebke and Barrientes, 2006; 
Bosserman et al., 2011).  An early study reported that T. vaginalis isolates exhibiting high 
MLCs determined by aerobic or anaerobic incubation were eradicated by standard 
metronidazole treatment (Muller et al., 1988).  Bosserman and colleagues recently assessed the 
utility of susceptibility testing for patient care (Bosserman et al., 2011).  Using a breakpoint for 
susceptibility of < 50 µg/ml, they reported that one-third of the isolates from women presenting 
with treatment failure were susceptible to metronidazole in the in vitro susceptibility assay.  
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The authors suggested that investigation of attainable intravaginal nitroimidazole 
concentrations in women with clinical treatment failure may contribute to a better 
understanding of this issue (Bosserman et al., 2011). 
 
Given that there is a limited number of drugs available for the treatment of T. vaginalis, several 
studies measured the activities of various antimicrobial agents against metronidazole 
susceptible and metronidazole resistant isolates (Bouma et al., 1998; Upcroft et al., 1999; 
Malagoli et al., 2002; Crowell et al., 2004; Blaha et al., 2006; Calzada et al., 2007; Goodhew 
and Secor, 2013; Afonso Silva Rocha et al., 2014; Badawy et al., 2014).  Although a few of 
these antimicrobial agents tested showed some activity (Chapter 4: Introduction), further 




2.9 DETECTION OF METRONIDAZOLE USING HIGH PERFORMANCE 
 LIQUID CHROMATOGRAPHY 
 
2.9.1 High Performance Liquid Chromatography  
 
The purpose of quantitative analysis of body fluids for any drug is to establish the 
distribution of that drug in the body.  This is usually done by monitoring drug concentrations 
during the dose-time interval. High performance liquid chromatography (HPLC) is most 
commonly used to measure drugs and their metabolites in body fluids such as blood and 
urine (Nikolin et al., 2004). HPLC has also been used for the determination of metronidazole 




HPLC has been developed to quantitate chemical substances in fluids and is capable of 
identifying different chemicals in a sample containing a mix (Kupiec, 2004; Olbrich and 
Corbett, 2013).  HPLC is a process by which outcome is determined by numerous variables 
such as column choice, temperature, mobile phase composition and pH (Bird, 1989; Olbrich 
and Corbett, 2013).  These various components need to be optimised for the detection of each 
individual compound and sample type (Olbrich and Corbett, 2013).  As shown in the schematic 
diagram in Figure 2.2 the HPLC system includes a pump, an injector, a column, a detector and 
a display system (Kupiec, 2004; Summerfield, 2010).   
 
Figure 2.2: A schematic diagram of a HPLC system (Summerfield, 2010) 
 
Pumps used in chromatography need to be able to generate high pressures of up to 6000 psi, to 
generate flow rates ranging from 0.1 to 10 ml/min with a flow reproducibility of 0.5 % or 
lower, to have pulse-free output and to be resistant to corrosion by the solvents used in the 
process (Skoog et al., 2004). HPLC involves the injection of the prepared sample into the 
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column which then retains the required compounds from the mobile phase (Olbrich and 
Corbett, 2013).  Samples are injected into the column by means of a sampling loop or an 
autosampler containing an automatic injector (Skoog et al., 2004).   
 
There are two ways of sample elution, i.e. isocratic and gradient elution.  A single mobile phase 
is used for the entire analysis with the isocratic method.  The gradient method involves 
changing the composition (two or more) of the mobile phase during the separation.  The flow 
rate of the mobile phase must be optimized to ensure efficient separation of the compound from 
the background. Mobile phases usually comprise of water, acetonitrile, and/or methanol. 
(Olbrich and Corbett, 2013).   
 
During HPLC separation takes place in the column which contains the stationary phase, which 
determines the efficacy of the HPLC method (Olbrich and Corbett, 2013).  Columns are 
usually made of stainless steel tubing and are between 10-30 cm in length (Skoog et al., 2004) 
with an inside diameter of 3-5 mm (Summerfield, 2010).  Columns are densely packed with 
silica particles leaving a pore size ranging from 3-10 µm (Skoog et al., 2004).  Hydrocarbon 
chains of variable length are bonded to these silica particles.  The most popular columns are the 
octadecyl carbon chain (C18) bonded silica and the C8-bonded silica.  There are two types of 
columns used in HPLC systems: normal phase and reverse phase columns (Olbrich and 
Corbett, 2013).  Reversed phase columns make use of hydrophobic columns and aqueous 
moderately polar mobile phases while normal phase columns are hydrophilic and use non-polar 
and non-aqueous mobile phases (Bird, 1989; Kupiec, 2004).  Reverse phase columns are used 
more frequently than normal phase columns mainly because of the extensive range of 
substances that can dissolve in the mobile phase.  The C8 and (C18) columns are commonly 
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used in reversed-phase HPLC (Olbrich and Corbett, 2013).  A guard column is positioned in 
front of the analytical column.  The guard column increases the lifespan of the analytical 
column by removing contaminants and particulate matter from the solvents (Skoog et al., 
2004). 
 
The retention or elution volume is the amount of mobile phase needed to draw the sample 
through the column (Kupiec, 2004).   The retention time refers to the length of time a sample is 
held in the column by the stationary phase in relation to the period it resides in the mobile 
phase (Kupiec, 2004).  The ability of the column to separate peaks on a chromatograph is 
referred to as the resolution (Kupiec, 2004).   
 
The detector senses the presence of a compound passing through the column and measures its 
concentration. It provides a quantitative electronic signal to the data acquisition system 
(Kupiec, 2004).  Detectors based on absorption of ultraviolet radiation are commonly used in 
liquid chromatography (Skoog et al., 2004).  The current HPLC systems use a computerised 
data acquisition system.  This system integrates the response of the detector and displays it as a 
chromatograph which may then be analysed (Kupiec, 2004). 
 
2.9.2 Detection of metronidazole by HPLC 
 
Metronidazole can be detected by microbiological techniques (bioassays), spectrophotometric 
methods, thin layer chromatography, gas-liquid chromatography, and HPLC (Turgut and 
Ozyazici, 2004; Klimowicz et al., 2002).  Earlier detection methods for metronidazole included 
bioassays and gas-liquid chromatography; however these methods were time-consuming and 
did not determine or separate the concentrations of the metabolites. HPLC methods have been 
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used to determine the concentrations of metronidazole and its metabolites in biological 
specimens, including urine (Nilsson-Ehle et al., 1981), gastric juice (Jessa et al., 1996) serum 
(Galmier et al., 1998; Larsen et al., 1986, Mattila et al., 1983), plasma (Ezzeldin and El-
Nahhas, 2012; Klimowicz et al., 2002; Emami et al., 1996;  Robertson et al., 1988), saliva 
(Jessa et al., 1996), vaginal tissue (Venkateshwaran and Stewart, 1995), and vaginal fluids 
(Robertson et al., 1988, Larsen et al., 1986).  It was previously reported that HPLC has a 
sensitivity to detect metronidazole at the nanogram level per gram of vaginal tissue 
(Venkateshwaran and Stewart, 1995).  As little as 5 ng of metronidazole was detected in serum 
using this method (Marques et al., 1978).  The analytical wavelength for detection of 
metronidazole ranges from 250 nm to 350 nm (Olbrich and Corbett, 2013, Galmier et al., 
1998). 
 
2.9.3 Pharmacokinetics and bioavailability of metronidazole 
 
Metronidazole is available as oral, intravenous, vaginal and topical formulations (Lofmark et 
al., 2010).  The bioavailability of oral metronidazole is approximately 100% (Simms-Cendan, 
1996).  Several studies have reported the penetration and distribution of metronidazole into 
various types of tissues and body fluids (Lamp et al., 1999).  Less than 20% of the circulating 
metronidazole is bound to plasma proteins (Lofmark et al., 2010).  Metronidazole is distributed 
in breast milk with concentrations similar to that found in serum (Simms-Cendan, 1996).  
Metronidazole has been reported to have good penetration into cerebrospinal fluid (CSF) and 
the central nervous system (CNS) (Turgut and Ozyazici, 2004; Lamp et al., 1999). Drug 
concentrations in the uterus and fallopian tubes were reported to be 94% and 97.3% of serum 
concentrations respectively 3 to 4 hours following oral administration (Elder and Kane, 1979 
cited by Lamp et al., 1999).  
28 
 
Metronidazole is metabolized in the liver into two major metabolites, (1-(2-hydroxy-ethy)-2-
hydroxy-methyl-5-nitroimidazole) and 2-methyl-5-nitroimidazole-1- acetic acid (Simms-
Cendan, 1996; Turgut and Ozyazici, 2004; Lofmark et al., 2010).  The acetic acid metabolite 
which is found in urine does not have any pharmacological activity.  Hydroxyl-metronidazole 
has an anti-microbial potency of approximately 30% that of metronidazole against 
metronidazole susceptible bacteria and can be detected in blood (Jessa et al., 1996; Turgut and 
Ozyazici, 2004,). The major route of elimination of metronidazole and its metabolites is by 
renal secretion. Biliary-fecal secretion is minimal (Lofmark et al., 2010).  
 




Typing of microbes belonging to one species is used as an epidemiological tool to establish lines 
of transmission of the microbe. This is based on the principle that isolates which are 
epidemiologically related result from the clonal expansion of a single parent isolate and 
consequently share characteristics that differ from isolates which are not epidemiologically 
related (Maslow et al., 1993; Arbeit, 1995).  Isolates belonging to the same type are referred to 
as a strain of the species.  A characteristic of an organism is useful for typing if it is stable within 
a strain and diverse within the species. The percentage of typeable isolates, reproducibility, 
discriminatory power, and ease of interpretation of the test and test results are important criteria 
for evaluating typing systems (Arbeit et al., 1995).  Ideally a typing method should be simple, 
rapid, inexpensive, reproducible and discriminatory.  Currently no single typing system fulfils 
all of these criteria, and therefore different typing methods are used for different organisms and 





2.10.2 Phenotyping  
 
Techniques such as biotyping, antibiotic susceptibility testing, serotyping, bacteriophage typing, 
electrophoretic protein typing with or without immunoblotting and multilocus enzyme analysis 
are all dependent on phenotypic characteristics for strain differentiation (Maslow et al., 1993, 
Arbeit et al., 1995.)  These typing methods are often limited by the capability of 
microorganisms to adjust the expression of such characteristics to environmental circumstances 
(Maslow et al., 1993).  Therefore, individual isolates of the same strain can vary phenotypically 
since some may not express one or more of the characteristics used for typing and as a 
consequence differ or are non-typeable (Arbeit et al., 1995).  Approaches to phenotyping of T. 
vaginalis isolates include, but are not limited to, electrophoretic protein typing (Boulos et al., 
2012) and multilocus enzyme electrophoresis (Proctor et al., 1988) 
 
Electrophoretic protein typing and immunoblotting 
 
Electrophoretic protein typing involves the isolation of whole-cell or cell-surface proteins and 
separation by SDS-PAGE.  The gel is thereafter stained to determine the resultant pattern 
(Maslow et al., 1993).  Immunoblotting involves the transfer of the separated products onto a 
nitrocellulose membrane and then labelling different proteins by means of antisera to certain 
antigens or with pooled human sera as a source of broadly reactive antibodies (Maslow et al., 
1993). The bound antibodies can then be detected using commercially available enzyme or 
fluorescent conjugates.  Variations in the proteins profiles can be detected by this method 
(Maslow et al., 1993).  Using electrophoretic analysis and immunoblotting Alderete et al (1986) 
detected a minor difference in a distinct protein among three of the four isolates examined.  A 
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recent study identified five different T. vaginalis strains among 20 T. vaginalis isolates using 
two dimensional gel electrophoresis without immunoblotting (Boulos et al., 2012).   
 
Multilocus enzyme electrophoresis  
 
Multilocus enzyme electrophoresis (MLEE) involves the detection of variations in the 
electrophoretic mobilities of individual soluble metabolic enzymes.  Starch gel electrophoresis is 
used for the separation of the cellular proteins of microorganisms.  Individual enzymes are then 
detected with the use of specific substrates (Whittam et al., 1983, Maslow et al., 1993).  Using 
MLEE one study characterised 32 T. vaginalis isolates into five groups (Soliman et al., 1982).   
Another study demonstrated the classification of 63 T. vaginalis isolates into 15 groups (Proctor 
et al., 1988) using MLEE.  This suggests a high discriminatory power for this method. 
 
2.10.3 Genotyping  
 
Genotypic typing techniques have several advantages. These techniques often have high 
discriminatory power and high reproducibility and can thus provide valuable insight into the 
epidemiology of pathogens (Van Belkum, 1994).  Approaches to genotyping of T. vaginalis 
isolates include, but are not limited to, pulsed field gel electrophoresis (Lehker and Alderete, 
1999; Upcroft et al., 2006a; Upcroft et al., 2009), random amplified polymorphic DNA analysis 
(Vanacova et al., 1997; Snipes et al., 2000, Kaul et al., 2004; Valadkhani et al., 2011; Rukasha 
et al., 2013), and PCR-restriction fragment length polymorphism (Stiles et al., 2000; Simões-
Barbosa et al., 2005; Crucittit et al., 2008, Meade et al., 2009; Kock et al., 2013).  More recent 
DNA-based techniques include multilocus sequence typing that assays single nucleotide 
polymorphisms (Cornelius et al., 2012) and microsatellite genotyping that determines the sizes 
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of tandem repeats of DNA in the genome (Prokopi et al., 2011, Conrad et al., 2011). 
 
Pulsed field gel electrophoresis  
 
Pulsed field gel electrophoresis (PFGE) can separate DNA sequences of up to several 
megabases in length (Lahiti, 1996).  There have been limited reports of the use of PFGE for 
typing T. vaginalis (Lehker and Alderete, 1999; Upcroft et al., 2006a; Upcroft et al., 2009).    
Upcroft and colleagues used PFGE together with a selection of gene probes to differentiate 
between 25 T. vaginalis isolates (Upcroft et al., 2006a).  Of these isolates, five were laboratory 
isolates from Australia and the United States of America and 20 were clinical isolates from 
South Africa.  The authors suggested that the pyruvate:ferredoxin oxidoreductase B gene probe 
is suitable for identifying epidemiologically related T. vaginalis isolates by PFGE (Upcroft et 
al., 2006a)  
 
Random amplified polymorphic DNA analysis 
 
The random amplified polymorphic DNA (RAPD) method of genotyping includes randomly 
amplifying segments of the target DNA by using a single primer that has no known homology 
to the target DNA sequence.  Several fragments of various sizes are generated by means of this 
PCR (Swaminathan and Matar, 1993).  RAPD analysis has been extensively used to genotype  
T. vaginalis isolates (Vanacova et al., 1997; Hampl et al., 2001; Rojas et al., 2004; Kaul et al., 
2004; Jamali et al., 2006; Valadkhani et al., 2011; Rukasha et al., 2013).  Studies have 
demonstrated that RAPD analysis was able to differentiate between T. vaginalis isolates 
obtained from asymptomatic and symptomatic patients (Rojas et al., 2004; Kaul et al., 2004; 
Jamali et al., 2006; Valadkhani et al., 2011).  Kaul et al (2004) showed that RAPD data 
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differentiated between T. vaginalis isolates from 15 symptomatic and 15 asymptomatic women. 
Using RAPD analysis Rojas et al (2004) reported differences amongst 40 isolates of T. 
vaginalis obtained from symptomatic and asymptomatic women.   
 
Multilocus sequence typing 
 
Multilocus sequence typing (MLST) distinguishes strains of microorganisms using internal 
sequence fragments of seven housekeeping genes (Aanensen and Spratt, 2005; Maiden, 2006), 
which are amplified by PCR and sequenced.  This method has been used to study populations 
of prokaryotic and eukaryotic pathogens (Tibayrenc, 2009).  A recent study reported that this 
method was able to distinguish 43 polymorphic nucleotide sites, 51 different alleles and 60 
sequence types amongst the 68 T. vaginalis isolates assessed (Cornelius et al., 2012). It was 
concluded that MLST is useful for investigating the epidemiology, genetic diversity and 





Microsatellites are short sequences of nucleotides organised in tandem repeats usually two to 
six base pairs in length (Conrad et al., 2011).  Single nucleotide polymorphisms (SNPs) which 
are bi-allelic genetic markers can also be used to study variations in DNA sequences (Conrad et 
al., 2011).  In order to study genetic diversity of T. vaginalis, a panel of 21 microsatellites and 
six single-copy genes from the T. vaginalis genome were identified and validated using seven 
T. vaginalis laboratory strains (Conrad et al., 2011).  High genetic diversity was observed when 
these markers were used to genotype over 200 T. vaginalis isolates obtained from different 





Polymerase chain reaction - restriction fragment length polymorphisms  
 
Polymerase chain reaction restriction fragment length polymorphisms (PCR-RFLP) entails 
amplifying a known DNA sequence and restriction of the resulting amplicons with restriction 
endonuclease enzymes.  Following gel electrophoresis, the polymorphisms are identified by 
differences seen in the restriction fragment sizes (Swaminathan and Matar, 1993).  This typing 
method can show minor variations in a gene where a single base variation (point mutation) has 
created or removed a recognition site for the restriction enzyme (Crucitti et al., 2008).  PCR-
RFLP has been used for typing of T. vaginalis (Simões-Barbosa et al., 2005; Crucitti et al., 
2008; Kock et al., 2013).   
 
Crucitti et al (2008) used PCR-RFLP with the actin gene as target. They identified eight T. 
vaginalis actin genotypes amongst 151 isolates from the Democratic Republic of Congo and 
Zambia (Crucitti et al., 2008).  PCR-RFLP analysis of T. vaginalis has also been performed 
using primers derived from the intergenic spacer (IGS) region of the ribosomal DNA (Simões-
Barbosa et al., 2005; Kock et al., 2013).  No genetic variation was found amongst 60 clinical 
isolates of T. vaginals by IGS–PCR RFLP with the use of eight restriction enzymes (Simões-
Barbosa et al., 2005).  Similarly in SA, Kock and colleagues reported no genetic differences 
amongst 92 T. vaginalis isolates using IGS-PCR RFLP; however they were able to 
discriminate between the same isolates using RAPD analysis (Kock et al., 2013).  The 






3.1 SPECIMEN COLLECTION AND PROCESSING 
 
This chapter provides a description of the methodology used for specimen collection as 
well as for culture, maintenance and storage of the T. vaginalis isolates.   
 
3.1.1 Specimen collection 
 
Vaginal specimens for culture of T. vaginalis were collected from the posterior vaginal 
fornix during speculum examination, using a dacron swab (Medical Wire and Equipment, 
UK).  Different cohorts of patients were used for the different parts of the study. These 
cohorts are described in the chapters reporting these studies. The swabs containing the 
specimens were immediately placed into 15 ml polypropylene conical screw-cap tubes 
(Evergreen Scientific, USA) containing 5 ml of selective Diamond’s trypticase–yeast 
extract–maltose (TYM) medium (Appendix A). Specimens were transported in this 
medium at room temperature to the laboratory within 4 to 12 hours from collection 
depending on the distance between site and laboratory.   
 
3.1.2 Growth requirements 
 
Diamond’s TYM medium was used for the culture and maintenance of the organism.  The 
medium was enriched with 10 % heat inactivated horse serum (South African Institute for 
Medical Research [SAIMR], now National Institute for Communicable Diseases [NICD], 
Johannesburg, South Africa). Antibiotics were added to inhibit growth of vaginal flora 
(amikacin [100 mg/ml], ampicillin [1 mg/ml], amphothericin B [5 mg/ml]).  Yeast extract 
was added before the medium was autoclaved, while the antibiotics and horse serum were 
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added aseptically afterwards. The pH of the medium was adjusted to pH 6.  Aliquots of 5 
ml of the medium were dispensed into 15 ml polypropylene conical screw-cap tubes 
(Evergreen Scientific, USA).  Prepared media was stored at 4oC and used within 2 weeks of 
preparation.  Quality control of the media was conducted by inoculating the media with T. 
vaginalis reference strain American Type Culture Collection (ATCC) 50138. 
 
3.1.3 Culture  
 
Cultures were performed in the tube in which the specimen was transported.  The tubes were 
placed at 37oC in a 5% CO2 enriched humidified incubator.  The addition of L-cystein in the 
medium and the low surface/column height ratio created an O2 gradient, decreasing from top 
to bottom of the tube, supporting growth of T. vaginalis in the O2 depleted lower regions.  The 
cultures were incubated for seven days.  The cultures were examined daily from day 2 to 7.  A 
drop of the culture medium was harvested aseptically from the bottom of the tubes and placed 
on a glass microscopy slide, covered with a glass coverslip and screened by standard light 
microscopy at a magnification of 100x and confirmed positive at 450x.  A diagnosis of T. 
vaginals infection was considered if cells of approximately 7 to 10 µm in diameter were 
observed showing the characteristic jerky motility.  A culture was deemed negative if no 
trichomonads were observed during 3 minutes of viewing at day 7.  A positive diagnosis was 
confirmed by an in-house polymerase chain reaction (Chapter 6), targeting a region within the 
Tv-E650 repeats (Paces et al., 1992).  Positive specimens were subcultured in Diamond’s 
TYM medium at 72 hour intervals in order to obtain non-contaminated axenic cultures.  
 
3.1.4 Storage  
 
Once non-contaminated axenic cultures were obtained, isolates were subcultured in antibiotic-
free Diamond’s TYM medium and stored at –70oC.  To prepare for storage dimethyl 
36 
 
sulfoxide (DMSO) (Sigma-Aldrich, USA) and inactivated horse serum were added to the T. 
vaginalis culture, to yield a final concentration of 10% and 15% respectively (Procter et al., 
1988).  The culture tubes were inverted 3 to 4 times to suspend the organisms evenly and to 
allow them to be coated with horse serum proteins and DMSO.  Aliquots of 1 ml of the 
culture were thereafter distributed into cryovials (Corning®, USA).  The cultures were frozen 
by means of a two-step process by placing them at –20oC for approximately 1 hour followed 
by transfer to –70oC for long term storage. 
 
3.1.5 Recovery of isolates from storage 
 
Vials of stored culture were removed from the –70oC freezer and placed in a water bath at 
37oC for 2 to 5 minutes until thawed.  The entire content of the vial was then inoculated into 
Diamond’s TYM medium which was pre-warmed to room temperature.  The inoculated 
media was placed in a 37oC C02 incubator.  After 24 hours, approximately 4 ml of the total of 
5 ml medium was siphoned off from the top to remove the DMSO.  This was replaced with 
fresh medium.  Wet mount microscopy, as described above (section 3.1.3), was performed 
after 48 to 72 hours.  If viable trichomonads were observed, a subculture was made into fresh 
antibiotic free medium.   
 
3.2 ETHICAL APPROVAL 
 
The study was approved by the Biomedical Research Ethics Committee (BREC) of the 









Treatment of patients with metronidazole-refractory vaginal trichomoniasis presents a 
major therapeutic challenge and treatment options are limited (Sobel et al., 2001).  
Although higher doses of metronidazole are often effective, many patients cannot tolerate 
this because of serious gastrointestinal discomfort (Cudmore et al., 2004).  Other patients 
are allergic to any concentration of the drug (Narcisi and Secor, 1996; Goodhew and Secor, 
2013).  Metronidazole resistance has been widely reported (Schwebke and Barientes, 2006; 
Upcroft et al., 2009; Bosserman et al., 2011; Kirkcaldy et al., 2012; Rukasha et al., 2013). 
Recently, in vitro metronidazole resistance was detected in 6% of T. vaginalis isolates 
obtained from thirty HIV infected women attending an anti-retroviral clinic in Pretoria, 
South Africa (Rukasha et al., 2013).   
 
In view of these reports of metronidazole resistance and the frequency of intolerance and 
allergic reactions to the 5-nitroimidazole drugs, alternative therapeutic options are needed 
(Secor, 2012; Goodhew and Secor, 2013).  Several compounds have been tested in vitro for 
efficacy against T. vaginalis (Blaha et al., 2006; Wright et al., 2010; Goodhew and Secor, 
2013; Afonso Silva Rocha et al., 2014).  Miltefosine (approved for treatment of visceral 
leishmaniasis) and nitazoxanide (approved for use against giardiasis and cryptosporidiosis) 
have shown efficacy in vitro and therefore have the potential to be effective in the 
treatment of trichomoniasis (Blaha et al., 2006; Wright et al., 2010; Secor, 2012; Afonso 
38 
 
Silva Rocha et al., 2014).  Goodhew and Secor (2013) tested 1040 drugs against 
metronidazole susceptible and resistant strains of T. vaginalis and found that none was as 
effective as any of the 5-nitroimidazole compounds.  However the study demonstrated that 
disulfiram and nithiamide may be effective and could be potentially used to treat 
individuals with hypersensitivity to 5-nitroimidazole drugs.  The authors also showed a 
synergistic effect of albendazole as well as coenzyme B12 with 5-nitroimidazoles and 
these may be useful in combination with metronidazole or tinidazole to treat individuals 
with clinically resistant trichomonas infection (Goodhew and Secor, 2013).  Further 
attempts to identify other suitable drugs to treat T. vaginalis infections are still necessary.  
 
This study consists of two parts.  The aim of the first part was to test metronidazole and six 
other antibiotics, some of which are recommended for use in the syndromic management 
of sexually transmitted diseases (WHO, 2003) for their potential activity against T. 
vaginalis.  This was done by standard broth macro-dilution.  In the second part of the study 
a broth micro-dilution method was used (Upcroft and Upcroft, 2001a) to measure the 
minimum inhibitory concentration (MIC) of metronidazole for a larger number of T. 
vaginalis isolates.  In addition, the MIC values obtained were correlated with clinical 
outcomes in a subset of the symptomatic patients who returned for follow up after 
receiving treatment according to syndromic management protocol. 
 
 
4.2 MATERIALS AND METHODS 
 






A total of 40 T. vaginalis isolates from patients in KwaZulu-Natal were included in this 
part of the study: nine isolates were obtained from females presenting with vaginal 
discharge syndrome at the STI clinic of the Prince Cyril Zulu Communicable Disease 
Centre in central Durban and 31 isolates were obtained from female sex workers at a truck 
stop on the N3 highway in the uThukela district in Kwazulu-Natal. The isolates were grown 
from vaginal specimens obtained as described in Chapter 3.  T. vaginalis American Type 
Culture Collection (ATCC) 50138, a resistant strain with known MIC for metronidazole 
(Muller et al., 1988), was used as control. 
 
4.2.1.2 Preparation of antibiotic stock solutions 
 
The antimicrobial agents used were metronidazole, ciprofloxacin, doxycycline, 
ceftriaxone, azithromycin, rifampicin and fluconazole.  Stock solutions of these antibiotics 
were prepared by dissolving an appropriate amount of each drug in its respective diluent 
(Appendix B).  The antibiotics as well as their respective solvents and diluents, are shown 
in Table 4.1.  Antibiotic stock solutions were used immediately to perform two fold 
dilutions or were stored at –20oC in 1 ml aliquots until required. The concentration range 














Table 4.1:  Diluents and solvents of antibiotics used in the broth macro-dilution assay 
 
Antibiotic Company Solvent Diluent 
Metronidazole Sigma-Aldrich, USA DMSO Distilled water 
Ciprofloxacin Bayer, Germany Distilled water Distilled water 
Doxycycline Pfizer, USA Distilled water Distilled water 
Ceftriaxone Roche, United Kingdom Distilled water Distilled water 
Azithromycin Pfizer, USA 95% ethanol Distilled water 
Rifampicin Pfizer, USA Methanol Distilled water 
Fluconazole Sigma-Aldrich, USA Distilled water Distilled water 
 
 
4.2.1.3 Inoculum preparation and standardization 
 
Each isolate of T. vaginalis was inoculated in duplicate in Diamonds media (Appendix A) 
and incubated at 37oC in a 5% CO2 enriched humidified incubator for 48 hours.  For the 
inoculum preparation, 500 µl of T. vaginalis culture was added to 5 ml of antibiotic-free 
Diamonds medium and incubated as above.  After 48 hours, the number of viable 
trophozoites was counted using a haemocytometer (Appendix C). Viability was established 
by means of trypan blue exclusion (Appendix C). The required inoculum of 1 x 104 viable 
trichomonads per ml was obtained by dilution with antibiotic free Diamond’s TYM 
medium.  
 
4.2.1.4 Drug susceptibility assay 
 
The broth macro-dilution method was used (Ralph et al., 1983).  Eleven 15 ml 
polypropylene conical screw-cap tubes (Evergreen Scientific, USA) were used to prepare 
the dilution series for each antibiotic. A volume of 9 ml of antibiotic-free Diamond’s TYM 
media was added to the first tube, and 5 ml to each to the remaining 10 tubes.  One 
millilitre of antibiotic pre-diluted stock solution (Appendix B) was then dispensed 
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aseptically into the first tube and mixed with the diluent by vortexing. Two-fold serial 
dilutions were performed by transferring 5 ml from the first tube to the next and so on. The 
tubes with antibiotic concentrations not falling within the test range were discarded.  
Diamond’s TYM medium with no antibiotic was used as growth control.  An amount of 
100 µl of the standardised trichomonad suspension was added to 5 ml of each of the tubes.  
The tubes were incubated for 48 hours at 37oC in a 5% CO2 enriched humidified incubator.  
Assays for each isolate were performed in duplicate. 
 
4.2.1.5 Determination of end points 
 
After 48 hours of incubation, the contents of each tube were mixed by inversion.  An 
aliquot was removed aseptically and viewed microscopically (described in Chapter 3) to 
determine if the cells showed motility.  The end point (MIC) of the assay was the minimum 
concentration of the drug at which no motile trichomonads were seen.  Motility was 
defined as active movement or stationary cells exhibiting movement of flagella and/or 
undulating membrane. 
 





One hundred and thirty women presenting with symptoms and signs compatible with vaginal 
discharge syndrome and 30 asymptomatic women were recruited from those attending the 
primary health and antenatal clinics at KwaMsane.  This is a semi-rural village in the Hlabisa 
sub-district of Kwazulu-Natal situated within the research area of The Africa Centre for 
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Health and Population Studies, an approximately 2.5 hour drive north of Durban, Kwazulu-
Natal.     
 
The syndromic management protocol for vaginal discharge syndrome which includes 
metronidazole (2 g single oral dose) was administered immediately to those women 
presenting with symptoms or on follow-up visit one week later if any of the diagnostic tests 
were positive in the asymptomatic patients.  For the purpose of the study the administration of 
single dose drugs as well the first dose of multi-dose drugs was observed.  Patients were asked 
to return for follow-up 7 to 10 days after treatment. 
 
4.2.2.2 T. vaginalis control strains 
 
Two control strains were included in all assays: one metronidazole resistant strain, 
STDL/B7268, isolated from a patient in Brisbane who suffered successive treatment failures 
over two years (Upcroft and Upcroft, 2001a) and a susceptible strain, BRIS/92/STDL/F1623 
(Upcroft and Upcroft, 2001a).  These strains were kindly donated by Jacqui and Peter 
Upcroft, Queensland Institute of Medical Research, Brisbane, Australia. 
 
4.2.2.3 Preparation of inoculum 
 
All isolates were grown in Diamond’s TYM medium as described in Chapter 3.  For the drug 
susceptibility assays isolates were incubated for 24 hours till the log phase of growth was 
reached (Upcroft and Upcroft, 2001a). Viable trophozoites were counted in a haemocytometer 





4.2.2.4 Drug susceptibility assays 
 
Susceptibility assays were performed as described previously (Upcroft and Upcroft, 2001a).  
Briefly, a 0.1M (17.1 mg/ml) stock solution of metronidazole (Sigma-Aldrich, USA) in N, N-
dimethylformamide (DMF) (HPLC grade, Sigma-Aldrich, USA) was prepared and stored at –
20oC.  This stock solution was diluted in Diamond’s TYM medium resulting in a 
concentration of 17.1 µg/ml (100 µM) as the highest concentration in the anaerobic assay.  A 
solution of DMF (189.6 µg/ml) without metronidazole was prepared in Diamonds medium 
and used as growth control.  A volume of 200 µl of diluted drug at 2x the final concentration 
was added to wells 1,3,4,6, etc. of row A and the drug free DMF solution to wells 2, 5, etc. of 
a 96 well flat bottomed, covered tissue culture plate (Corning-Costar®, USA) and 100 µl of 
drug free medium was added to all other wells as diluent.   
 
Double dilutions were performed down the plate (Figure 4.1) and the last 100 µl from each 
well of row H was discarded.  The final concentrations of metronidazole after addition of the 
inoculum in the anaerobic assay ranged from 17.1 µg/ml (100 µM) to 0.1 µg/ml (0.8 µM).  
The same procedure was followed for the aerobic assay. The final concentrations of 
metronidazole in this assay ranged from 34.2 µg/ml (200 µM) to 0.3 µg/ml (1.57 µM). 
 
Equal volumes (100 µl) of the required inoculum were added to all wells.  For each isolate 
and drug concentration there were four wells with drug and two without.  The plates were 
placed in the incubation bags and an Anaerocult® C mini sachet (Merck, Germany) was 
added. The bag was sealed and placed in a regular 37oC incubator.  Aerobic assays were 




 Isolate A Isolate B 
 
Lane 1 2 3 4 5 6 7 8 9 10 11 12 
Drug* 
dilution 
M D M M D M M D M M D M 
Row A 
(100µM) 
            
Row B 
(50µM) 
            
Row C 
(25µM) 
            
Row D 
(12.5µM) 
            
Row E 
(6.25µM) 
            
Row F 
(3.12µM) 
            
Row G 
(1.6µM) 
            
Row H 
(0.8µM) 
            
*Drug dilution series for anaerobic assay represented       M – Metronidazole                D – DMF only  
 
Figure 4.1: Diagrammatic representation of the 96-well microtiter test plate   
 
4.2.2.5 Scoring and determination of end points 
 
Using an inverted microscope, trophozoite growth was monitored daily, for up to 72 hours, 
comparing control and drug containing wells in the same row (Upcroft and Upcroft, 2001a).  
The anaerobic plates remained in the incubation bags during this procedure.  This ensured that 
there was no fluctuation of the anaerobic environment throughout the incubation period.  A 
standardised scoring system was used to establish the MICs, with scores varying from 1+ to 
4+ (Table 4.2).    
 
Table 4.2: Scoring of T. vaginalis growth in the broth micro-dilution assay 
T. vaginalis growth Score 
0-10 motile parasites; not more than 20% 
coverage of well surface 
1+ 
> 10 motile parasites; 20% to 50% coverage of 
the well surface 
2+ 
> 50 % coverage of the well surface = almost 
confluent growth with much motility 
3+ 
confluent growth with full motility  4+ 
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T. vaginalis was monitored for motility and/or percentage well coverage.  MIC values were 
defined as the lowest concentration of drug at which a 1+ score was obtained in at least three 





4.3.1 Susceptibility testing of T. vaginalis to syndromic management and anti- 
protozoal drugs using broth macro-dilution MIC determination 
 
4.3.1.1 Broth macro-dilution MIC test results 
 
Table 4.3 shows the distribution of the MICs in the 40 isolates. All 40 clinical isolates were 
susceptible to metronidazole with a MIC range of < 0.125 – 0.5 µg/ml.  Strain ATCC 
50138 displayed the expected MIC >128 µg/ml.  As to be expected, ceftriaxone had no 
inhibitory effect on T. vaginalis.  No inhibition was observed with fluconazole.  While 
azithromycin and ciprofloxacin had an inhibitory effect, this was only seen at 
concentrations of 64 µg/ml or higher.  Rifampicin showed similar results.  The MICs for 
doxycycline were lower than for any of the other drugs, confirming its effect on protozoa 









Table 4.3:  Distribution of T. vaginalis isolates inhibited at given MIC values (n = 40) 
Antibiotic No of isolates with MIC (μg/ml): 
< 0.125 0.25 0.5 1 2 4 8 16 32 64 128 >128 
Metronidazole 34 5 1 - - - - - - - - - 
Ciprofloxacin - - - - - - - - - 6 17 17 
Doxycycline - - - - - 1 12 23 4 - - - 
Ceftriaxone - - - - - - - - - - - 40 
Azithromycin - - - - - - - - - 3 27 10 
Rifampicin - - - - - - - -- 1 11 6 22 
Fluconazole - - - - - - - - - - - 40 
 
 
The cumulative MICs are shown in Table 4.4.  The MIC required to inhibit the growth of 
90% of organisms (MIC90) was 0.25 µg/ml for metronidazole, 16 µg/ml for doxycycline, 
and > 128 µg/ml for ceftriaxone, azithromycin, rifampicin, ciprofloxacin and fluconazole. 
 
Table 4.4: Cumulative MICs of T. vaginalis isolates (n = 40) 
Antibiotic Cumulative % of isolates with MIC (μg/ml): 
 ≤ 0.125 0.25 0.5 1 2 4 8 16 32 64 128 >128 
Metronidazole 85 97.5 100 - - - - - - - - - 
Ciprofloxacin - - - - - - - - - 15 57.5 100 
Doxycycline - - - - - 2.5 32.5 90 100 - - - 
Ceftriaxone - - - - - - - - - - - 100 
Azithromycin - - - - - - - - - 7.5 75 100 
Rifampicin - - - - - - - - 2.5 30 45 100 






4.3.2 Susceptibility testing of T. vaginalis to metronidazole using the broth  
micro-dilution method  
 
4.3.2.1 Metronidazole MICs of T.vaginalis isolates with broth micro-dilution  
 
Table 4.5 shows the metronidazole MIC distribution of the 160 isolates obtained with broth 
micro-dilution under aerobic and anaerobic incubation conditions.  In the aerobic assay the 
MIC of all T.vaginalis isolates ranged from 1.1 µg/ml to > 34.2 µg/ml (6.25 µM to > 200 
µM) with an average of 9.5 µg/ml (55 µM) after 48 hours of incubation and from 0.3 
µg/ml to > 17.1 µg/ml (1.6 µM to > 100 µM) and an average of 2.6 µg/ml (15.2 µΜ) in the 
anaerobic assay. After 72 hours the averages were (6.5 µg/ml) (38 µΜ) and 2.1 µg/ml (12 
µΜ) respectively with identical ranges. The MICs of the controls were within the expected 
range (Upcroft and Upcroft, 2001a). 
 
Table 4.5: Distribution of metronidazole MICs of 160 T. vaginalis isolates incubated    
aerobically and anaerobically 
 
MIC   Incubation time and conditions 












≤ 0.1 ≤ 0.8 nt 0 nt 0 
0.3 1.6 0 2 0 11 
0.5 3.13 0 20 0 25 
1.1 6.25 1 46 1 55 
2.1 12.5 8 60 39 51 
4.3 25 46 19 56 7 
8.6 50 66 9 47 8 
17.1 100 35 2 16 2 
> 17.1 > 100 nt 2 nt 1 
34.2 200 3 nt 0 nt 
> 34.2 > 200 1 nt 1 nt 
Dilution range – aerobic incubation: 34.2 to 0.3 µg/ml 
Dilution range – anaerobic incubation: 17.1 to 0.1µg/ml 
nt = not tested 
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Table 4.6 shows the cumulative % of MICs obtained under anaerobic and aerobic 
incubation conditions. After 72 hours aerobic incubation the MIC90 was 8.6 µg/ml. Under 
anaerobic incubation, the MIC90 was between 2.1 and 4.3 µg/ml.   
 
Table 4.6: Cumulative % of metronidazole MICs of 160 T. vaginalis isolates incubated    
aerobically and anaerobically. 
 
MIC Incubation time and conditions 












≤ 0.1 ≤ 0.8 nt 0 nt 0 
0.3 1.6 0 1.3 0 6.9 
0.5 3.13 0 13.8 0 22.5 
1.1 6.25 0.6 42.6 0.6 56.9 
2.1 12.5 5.6 80.1 25 88.8 
4.3 25 34.4 92 60 93.2 
8.6 50 75.7 97.6 89.4 98.2 
17.1 100 97.6 98.9 99.4 99.5 
> 17.1 > 100 nt 100 nt 100 
34.2 200 99.5 nt 0 nt 
> 34.2 > 200 100 nt 100 nt 
Dilution range – aerobic incubation: 34.2 to 0.3 µg/ml 
Dilution range – anaerobic incubation: 17.1 to 0.1 µg/ml 
nt = not tested 
 
 
4.3.2.2 Response to treatment 
 
Of the 130 symptomatic patients, 56 (43%) returned for follow up after 7 to 10 days of 
administering of the metronidazole. Thirty two (57%) of these 56 patients were co-infected 
with HIV. A follow-up specimen was available for 48/56 (86%). Clinical response to 
treatment was observed in 51/56 (91%) patients. Microbial eradication was seen in 42/48 
(88%). No statistically significant difference in clinical response (p = 0.379) or microbial 






Table 4.7:  Clinical response and microbial eradication in HIV negative and HIV positive  
patients  
 
 HIV + HIV - P-value 
Clinical Response 88% 96% 0.379 
Microbial Eradication 92% 82%     0.392  
 
 
Table 4.8 and Table 4.9 show the MIC distribution and the cumulative MICs of the 56 pre-
treatment isolates of T. vaginalis.   After 72 hours of aerobic incubation the MIC90 was 8.6 




Table 4.8: Distribution of metronidazole MICs of 56 pre-treatment isolates of T. vaginalis    
incubated aerobically and anaerobically for 72 hours 
 
MIC Incubation  conditions 
μg/ml µM Aerobic  Anaerobic  
≤ 0.1 ≤ 0.8 nt 0 
0.3 1.6 - 2 
0.5 3.13 0 11 
1.1 6.25 0 19 
2.1 12.5 13 13 
4.3 25 15 3 
8.6 50 22 5 
17.1 100 5 2 
> 17.1 > 100 nt 1 
34.2 200 0 nt 
> 34.2 > 200 1 nt 
Dilution range – aerobic incubation: 34.2 to 0.3 μg/ml 
Dilution range – anaerobic incubation: 17.1 to 0.1 μg/ml 















Table 4.9: Cumulative % of metronidazole MICs of 56 pre-treatment isolates of T.    
vaginalis incubated aerobically and anaerobically for 72 hours 
 
MIC Incubation conditions 
μg/ml µM Aerobic  Anaerobic  
≤ 0.1 ≤ 0.8 nt 0 
0.3 1.6 0 3.6 
0.5 3.13 0 23.2 
1.1 6.25 0 57.1 
2.1 12.5 23.2 80.3 
4.3 25 50 85.7 
8.6 50 89.3 94.6 
17.1 100 98.2 98.2 
> 17.1 > 100 nt 100 
34.2 200 0 nt 
> 34.2 > 200 100 nt 
Dilution range – aerobic incubation: 34.2 to 0.3 μg/ml 
Dilution range – anaerobic incubation: 17.1 to 0.1 μg/ml 
nt = not tested 
 
 
4.3.2.3 Association between MIC and response to treatment 
 
Of the patients that, according to the aerobic assay (72 hours), were infected with isolates 
with respective MICs of ≤ 4.3 µg/ml or 8.6 µg/ml, 24/28 (86%), and 22/22 (100%) 
responded to treatment.  Five of the six patients infected with isolates having MICs of ≥ 
17.1 µg/ml responded to treatment as well. The association with MICs obtained with the 
anaerobic assay read after 72 hours of incubation showed similar associations but at lower 
MICs.  Of the patients infected with an isolate with MIC ≤ 1.1 µg/ml, 28/32 (88%) 
responded to treatment while for those with isolates with MIC = 2.1 µg/ml and MIC ≥ 4.3 
µg/ml the response rates were 13/13 (100%) and 10/11 (91%) respectively.  Figure 4.2 (a-
b) shows the MIC distribution of pre-treatment isolates of those that responded to 
syndromic management treatment and those that did not after 72 hours of aerobic and 
anaerobic incubation. There is a trend towards MICs being lower for the responders. 

















































MIC µg/ml b  
Figure 4.2: MIC distribution T. vaginalis isolates of responders and non-responders after 72 
hours of aerobic and anaerobic incubation: (a) aerobic incubation; (b) anaerobic incubation. 
 
4.3.2.4 Association between pre-treatment MICs and microbial eradication 
 
Follow up culture results were available for 48 of the 56 patients that came back for follow 
up. When the Upcroft and Upcroft (2001a) breakpoints were applied, the following was 
observed: after 72 hours of aerobic incubation, microbial eradication was achieved in 22/24 
(92%) of those infected with isolates with MICs of ≤ 4.3 µg/ml, 17/20 (85%) with MICs of 
8.6 µg/ml and 3/4 (75%) with MICs of ≥ 17.1 µg/ml. In the anaerobic assay (after 72 hours 
of incubation), these figures were 24/26 (92%) of the patients infected with a isolate with 
an MIC of ≤ 1.1 µg/ml, 11/13 (85%) infected with isolates with MICs of 2.2 µg/ml, and 
7/9 (78%) with isolates with an MIC of ≥ 4.3 µg/ml. Figure 4.3 (a-b) shows MIC 
distribution of microbial eradication after 72 hours of aerobic and anaerobic incubation.  
There is a trend towards MICs being lower in those patients where microbial eradication 
was achieved. However, MICs of isolates without eradication were evenly distributed 














































MIC µg/ml b  
Figure 4.3: Microbial eradication and MIC distribution after 72 hours of aerobic and anaerobic 





In the first part of this study, the MICs of 40 T. vaginalis isolates and one metronidazole 
resistant reference strain were performed using the broth macro-dilution method (Ralph et 
al., 1983).  At the time of the study, three of the drugs tested (metronidazole, doxycycline 
and ciprofloxacin), were used as part of the syndromic management package for treatment 
of vaginal discharge syndrome (Moodley et al., 2003).  Currently, ceftriaxone has replaced 
ciprofloxacin (Lewis and Maruma, 2009). These drugs were tested to establish whether 
there would be additional antimicrobial effect on T. vaginalis when used in combination 
with metronidazole during syndromic management of sexually transmitted diseases.  Of 
the remaining three drugs azithromycin and rifampicin were chosen for their potential 
effect on protozoal parasites and fluconazole because of the frequent addition of this drug 
to treatment regimens for vaginal infections. 
 
Azithromycin which has a broad spectrum of antibacterial activity (Davis, 2011) has been 
used for treatment of infections caused by protozoan parasites, such as Toxoplasma gondii 
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(Nasta and Chiodera, 1997) and Plasmodium falciparum (Miller et al., 2006).  Rifampicin 
inhibits the prokaryotic RNA polymerase (Campbell et al., 2001). This drug could 
therefore have an inhibitory effect on T. vaginalis since this organism shares characteristics 
with prokaryotic microbes. Azithromycin, rifampicin and ciprofloxacin showed some 
inhibitory effect but at concentrations which are for bacteria in the resistant range. These 
three drugs should be tested for synergistic effect with metronidazole. 
 
The results of this study demonstrated that ceftriaxone and fluconazole were not effective 
in vitro when tested against the 40 T. vaginalis isolates. This does not exclude a synergistic 
effect when tested in combination with metronidazole. 
 
Doxycycline is a tetracycline derivative (Tikka et al., 2001). These drugs have shown to 
have anti-protozoal effect, e.g. doxycycline is used for malaria prophylaxis (Tan et al., 
2011).  The results of this study show that doxycycline also affects T. vaginalis.  Of the 40 
isolates 13 (33%) had an MIC < 8 µg/ml which is a concentration achievable in serum with 
an oral dose of 500 mg (Adadevoh et al., 1976).  To our knowledge there have been no 
reports on its concentration in vaginal secretions. Whether the MICs in this range translate 
in contribution to the effect of syndromic management of patients with vaginal discharge 
syndrome caused by T. vaginalis cannot be concluded from this study.  Possible synergistic 
effect of metronidazole with the different tetracycline derivatives should be studied.  Of 
note, one study showed that doxycycline given at 2 x 200 mg/day for 7 days had no 
therapeutic effect on patients infected with T. vaginalis (Mahdi et al., 2006). However, 
only three patients were included and MICs were not performed. With doxycycline MICs 
ranging between 4 and 32 µg/ml this drug did affect all T. vaginalis isolates in vitro except 
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the metronidazole resistant reference strain.  This strain was not inhibited by 128 µg/ml.  
This suggests the presence of a resistance mechanism in T. vaginalis for tetracyclines.  
Whether this is a mechanism leading to resistance to both metronidazole and doxycycline 
together (as in this strain) warrants further investigation. 
 
Given that there are limited treatment options for trichomoniasis currently, and that clinical 
failure of 5-nitro-imidazole treatment of trichomoniasis has been reported (Lossick et al., 
1986; Muller et al., 1988; Schwebke and Barientes, 2006; Kissinger et al., 2008; 
Bosserman et al., 2011), it is imperative that standardised and reproducible susceptibility 
tests with good clinical predictive value (Doern and Brecher, 2011) are available.   
 
The problem of assessing T. vaginalis resistance to metronidazole is compounded by the 
lack of universally recognized breakpoints for clinical resistance.  Many different methods, 
reporting on either MICs or minimum lethal concentrations (MLCs), are used to test for 
drug susceptibility.  Furthermore it is not possible to define accurate threshold values for 
resistant and sensitive strains without correlating outcome with pharmacokinetics, 
reinfection and MIC and/or MLC.  
 
A variety of breakpoints (Table 4.10) have been used to differentiate between resistant and 
susceptible T. vaginalis isolates with incubation times varying from 24 to 72 hours 
(Lossick et al., 1986; Meri et al., 2000; Stiles et al., 2000; Upcroft and Upcroft, 2001a; 





















µg/ml µM µg/ml µM 
Susceptible < 50 < 292 < 3.1 < 18 48 hours Lossick et al 
(1986) Resistant ≥ 50 > 292 ≥ 3.1 ≥ 18 
     
Susceptible ≤ 75 ≤ 439 ≤ 15 ≤ 88 24 and 48 
hours Meri et al (2000) Resistant > 75 > 439 > 15 > 88 
     
Susceptible  < 10 < 58 - - 24 hours 





58-585 - - 
High level 
resistance  
≥100 ≥ 585 - - 
       
Susceptible < 4.3 < 25 < 1.1 < 6.25 48 and 72 
hours Upcroft and Upcroft, (2001a) Intermediate 8.6 50 2.1 12.5 Resistant > 17.1 > 100 > 4.3 > 25 
     
Practically no 
resistance 









50 292 - - 
Low resistance 100 585 - - 
Moderate 
resistance 
200 1170 - - 
High resistance > 200 > 1170 - - 





- - 48 hours 

















High resistance > 400 > 2339 - - 
     
Susceptible < 50 < 292 - - 48 hours 









200 1170 - - 




After comparing in vitro test results of isolates from clinical treatment failures and 
responders, Upcroft and Upcroft, (2001a) proposed aerobic and anaerobic breakpoints, for 
categorising isolates as susceptible, intermediate and resistant as shown in Table 4.10.  
Overall, breakpoints proposed by Upcroft and Upcroft (2001a) are much lower in 
comparison to the other breakpoints listed in Table 4.10. 
 
Table 4.11 shows the classification of the 160 isolates from the second part of the study as 
susceptible, intermediate or resistant after 48 and 72 hours of incubation according to 
breakpoints identified by Upcroft and Upcroft, 2001a (Table 4.10).  The MICs shifted 
towards lower readings after 72 hours of incubation in both aerobic and anaerobic 
environments. According to these breakpoints the MICs obtained after 72 hours under 
aerobic and anaerobic conditions both displayed metronidazole resistance in approximately 
11% of isolates.  Four isolates were resistant under both aerobic and anaerobic incubation.  
Over 50% of isolates were susceptible after 72 hour of incubation under both aerobic and 
anaerobic incubation. Although the broth micro-dilution method applied here is 
reproducible, further improvement of the assays may still be necessary. A higher drug 
dilution range together with an incubation period longer than 72 hours may result in more 
precise detection of true clinically resistant isolates. 
 
Table 4.11: Interpretation of susceptibility assays using Upcroft and Upcroft (2001a)         
breakpoints 
Number (%) of T. vaginalis Isolates (n = 160) 
 Susceptible Intermediate Resistant 
Incubation* 48 hours 72 hours 48 hours 72   hours 48 hours 72 hours 
Aerobic 55 (34) 96 (60) 66 (41) 47 (29) 39 (24) 17 (11) 
Anaerobic 68 (43) 91 (57) 60 (38) 51 (32) 32 (20) 18 (11) 
* row: incubation period; column: incubation environment  
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Applying the Upcroft and Upcroft (2001a) breakpoints (Table 4.10) to the 56 pre-treatment 
isolates, 28 (50%) were susceptible and 6 (11%) were resistant to metronidazole after 72 
hours of aerobic incubation. The remaining 22 (39%) were inhibited at the concentration in 
between the two breakpoints. After 72 hours of anaerobic incubation, 32 (57%) of the 56 
pre-treatment isolates were susceptible, 11 (21%) were resistant, and 13 (23%) were 
inhibited at the concentration in between the two breakpoints.  Only two isolates were 
resistant under both aerobic and anaerobic incubation.  
 
Most studies found that high MICs obtained aerobically correlate better with treatment 
failure (Lossick et al., 1986; Muller et al., 1988).  Our study demonstrated that in vitro 
resistance in clinical isolates occurred under both aerobic and anaerobic conditions.  We 
however did not find a correlation between treatment failure and resistance as only one 
isolate from a patient with treatment failure was resistant under both incubation 
environments (Table 4.12). 
 
Based on the MIC breakpoints proposed by Upcroft and Upcroft (2001a), the distribution 
of MICs, obtained aerobically, in the 56 pre-treatment isolates in this study suggests that 
approximately 11% of patients diagnosed with trichomoniasis were infected with a 
resistant strain. This did however not correspond with clinical response, as treatment in 
only one of six patients with a resistant isolate failed both clinically and microbiologically 






Table 4.12: Clinical response in metronidazole resistant pre-treatment isolates (n = 6) 
Isolate Aerobic incubation* 
(72 hours) MIC: 
Anaerobic** 




µg/ml µM µg/ml µM 
1 17.1 100 2.1 12.5 YES 
2 17.1 100 17.1 100 YES 
3 17.1 100 1.1 6.25 YES 
4 17.1 100 1.1 6.25 YES 
5 17.1 100 0.5 3.13 YES 
6 > 34.2 > 200 > 17.1 > 100 NO 
        *   Upcroft and Upcroft (2001a) and Stiles et al (2000) breakpoints 
                    ** Upcroft and Upcroft (2001a) breakpoints    
  
 
The T. vaginalis resistant isolate from this patient displayed an MIC of > 34.2 µg/ml (> 
200 µM)) at both 48 hour and 72 hour readings in the aerobic assay and a MIC of > 17.1 
µg/ml (> 100 µM) at both 48 hour and 72 hour readings in the anaerobic assay.  According 
to Upcroft and Upcroft (2001a), these MICs represent metronidazole resistance. The only 
MIC value not found in any of the isolates of the 48 patients that responded to treatment, 
and in in whom microbial eradication was achieved was > 34.2 µg/ml (> 200 µM), under 
aerobic incubation. Based on the observations in this patient the Upcroft and Upcroft 
(2001a) aerobic breakpoint for resistance may be too low.  
 
Susceptibility classification of the 56 pre-treatment isolates varied when each of the 
breakpoints listed in Table 4.10 were applied for the MICs obtained in the aerobic assay 
after 72 hours of incubation.  As per the breakpoints described by Stiles et al (2000), 6/56 
(11%) isolates would be categorized as moderately resistant. However, not all of these six 
isolates (Table 4.12) were part of the eight patients (Table 4.13) with unsatisfactory 
outcome. Only one of the eight isolates from the latter group (Table 4.13) was amongst the 
six isolates also classified as resistant according to the Stiles et al (2000) aerobic 
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breakpoint. The other five isolates classified as resistant did respond to treatment. Whether 
this response is the result of synergistic effect of one or more of the drugs in the syndromic 
management package or because of inaccuracy of the Stiles et al (2000) breakpoint, needs 
further investigations.   
 
According to the Lossick et al (1986), Meri et al (2000); Kissinger et al (2008) and 
Bosserman et al (2011) breakpoints all 56 isolates would be categorized as susceptible, or 
having practically no resistance according to Schwebke and Barrientes (2006). This 
includes all eight isolates of the patients with unsatisfactory outcome.   
 

















µg/ml µM µg/ml µM 
1 4.3 25 1.1 6.25 No Not Done Neisseria 
gonorrhoeae, 
syphilis, HIV 
2 8.6 50 2.1 12.5 Yes + BV (NS = 10) 
3 4.3 25 0.3 1.6 No + BV (NS = 10) 
4 8.6 50 2.1 12.5 Yes + BV (NS = 8) 
5 4.3 25 1.1 6.25 No - BV (NS = 4), 
yeast, HIV 
6 4.3 25 1.1 6.25 No + BV (NS = 7), 
yeast, HIV 
7 8.6 50 8.6 50 Yes + BV (NS = 7) 
8 > 34.2 > 200 > 17.1 > 100 No +   BV (NS = 9), HIV 
* Upcroft and Upcroft (2001a) breakpoints 
BV = bacterial vaginosis 
NS = Nugent’s score 
 
Table 4.13 summarises the data of the eight patients without clinical and/or 
microbiological response to treatment. Six patients still harboured a T. vaginalis isolate on 
follow-up visit. These observations may be explained by comorbidity. Of the six patients 
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that were culture positive on follow-up, three reported clinical response while the other 
three did not. The MICs of the organisms in all eight patients varied from 4.3 µg/ml (25 
µM) to > 34.2 µg/ml (> 200 µM) in the aerobic assay and from 0.3 µg/ml (1.6 µM) to > 
17.1 µg/ml (> 100 µM) in the anaerobic assay.  
 
A single observed oral dose of metronidazole was administered to all patients in this study, 
including those that reported for follow-up. Hence, treatment failure cannot be explained 
by non-adherence. Lack of efficacy of the drug may be based on differences in 
susceptibility of isolates, on differences in metronidazole pharmacokinetics between 
patients, early reinfection or non-response to treatment of concomitant infections with 
other STI pathogens.  
 
In patient 1, no follow up culture was done.  The low MICs of the pre-treatment isolate 
may suggest response to metronidazole treatment and the lack of clinical response could be 
due to ciprofloxacin resistance in the N. gonorrhoeae isolate (Moodley et al., 2004). 
However, both of this is speculation. 
Patient 2, 4 and 7 responded clinically but there was no eradication of the T. vaginalis.  All 
three also had high bacterial vaginosis (BV) scores.  The observation of clinical response 
of vaginal discharge syndrome is subjective, both by the patient and the clinician.  It is 
therefore possible that these patients’ symptoms improved due to the effect of treatment of 
the BV but that the trichomiasis was still symptomatic although less severe.  This means 
clinical resistance of the T. vaginalis while the MICs were low. 
Patient 3, 6 and 8 showed no clinical response and there was no eradication of the T. 
vaginalis. All three had a high BV score.  The lack of clinical response in these three 
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patients could have resulted from early recurrence of BV after single dose metronidazole 
treatment (Moodley et al., 2003).  However, the presence of yeasts in combination with a 
Nugent score of 7 in patient 6 could also be compatible with candidiasis (Apalata et al., 
2014). The persistence of the T. vaginalis in patient 8 can also be the result of 
metronidazole resistance since this isolate showed high MICs. 
Patient 5 did not respond clinically but there was eradication of T. vaginalis.  This patient 
also had yeasts on pre-treatment microscopy.  The absence of response to treatment could 
be the result of pre-existing candidiasis with colonisation with T. vaginalis or the 
development of candidiasis due to antimicrobial treatment.  
 
Some patients had persistent infection with an organism with a MIC below the Upcroft and 
Upcroft (2001a) breakpoint for resistance (Table 4.13).  It may be possible that these 
patients were re-infected directly after treatment, or there may have been incomplete 
absorption of the drug from the gut or poor secretion into the vagina (Kane et al., 1961).  
Like in the gut (van Saene, 1985), there could have also been inactivation of the drug by 
the vaginal flora.  Most resistant isolates were eradicated from our 56 patients by the 2 g 
single dose of metronidazole. Thus microbiological and/or clinical cure does occur with 
organisms that have high levels of in vitro resistance.  As demonstrated in several studies 
(Lossick et al., 1986; Muller et al., 1988; Schwebke and Barrientes, 2006; Bosserman et 
al., 2011) including ours, treatment outcome seems not to correlate with in vitro 
susceptibility of the organisms to metronidazole. This needs to be addressed in 




Table 4.14 shows the comparison between cumulative MICs in the broth macro- and 
micro-dilution assays in this study.  We found that the isolates tested using the broth 
macro-dilution assay displayed lower MICs compared to the isolates tested using the broth 
micro-dilution method.  Direct comparison of the two assays cannot be made as different 
methodologies and isolates were used in the assays.  Meingassner and Thurner (1979) 
compared two T. vaginalis strains (one metronidazole resistant and one metronidazole 
susceptible) using the broth macro- and micro-dilution methods.  They reported a 32-fold 
difference in the MLCs of the two strains tested in the aerobic broth micro-dilution assay 
yet only minor differences were noted between the same two strains in the broth macro-
dilution assay. They suggested that the broth micro-dilution method may be a more 
suitable method for susceptibility testing of the resistant strain since the assay could be 
conducted under both aerobic and anaerobic conditions ((Meingassner and Thurner, 1979). 
 
 
Table 4.14: Comparison between the broth macro- and micro-dilution methods  




Cumulative % of isolates with MIC (μg/ml): 
 ≤ 0.1 0.3 0.5 1.1 2.1 4.3 8.6 17.1 >17.1 
Broth macro-dilution 
(48 hour incubation) 
(Study 1) (n = 40) 
85 97.5 100 - - - - - - 
Broth micro-dilution (48 
hour incubation) (Study 
2) (n = 160) 
- 1.3 13.8 42.6 80.1 92 97.6 98.9 100 
Broth micro-dilution (72 
hour incubation) (Study 
2) (n = 160) 
- 6.9 22.5 56.9 88.8 93.2 98.2 99.5 100 
Dilution range – broth macro-dilution: 128 to 0.125 µg/ml 
Dilution range – broth micro-dilution: 17.1 to 0.1 μg/ml  
 
 
Comparison of results of published studies on T. vaginalis susceptibility is challenging 
since various methods have been used for testing of metronidazole susceptibility, and 
results are reported as either MIC or MLC.  The differences observed in susceptibility 
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patterns when applying the different breakpoints (Table 4.10) to our set of susceptibility 
data underscores the need for the development of globally accepted breakpoints for each 
method.  This would facilitate standardised reporting and direct comparisons of the degree 






DETERMINATION OF METRONIDAZOLE CONCENTRATION IN 
VAGINAL SECRETIONS USING A NON-INVASIVE SPECIMEN 




Clinical failures of metronidazole treatment in women with trichomoniasis have been reported 
(Muller et al., 1988; Schwebke and Barrientes, 2006; Bosserman et al., 2011).  Several factors 
such as non-adherence to treatment, poor absorption of the drug from the gastro-intestinal 
tract, limited secretion into the vagina, inactivation of the drug by vaginal flora, and drug-
resistance of T. vaginalis ((Kane et al., 1961; Kellock and Mahony, 1996; Secor, 1996; Seña 
et al., 2014) may contribute to treatment failure.   Although metronidazole has been used for 
over four decades, very little information is available on the concentration of metronidazole in 
vaginal secretions after oral administration of the drug (Larsen et al., 1986).  Several studies 
(Muller et al., 1988; Schwebke and Barrientes, 2006; Bosserman et al., 2011), including ours 
(Chapter 4) have shown poor correlation between in vitro resistance of T. vaginalis to 
metronidazole and treatment outcome.  Investigating the levels of metronidazole in vaginal 
secretions will assist in the development of an in vitro susceptibility methodology with 
breakpoints that are better able to predict treatment outcome.   
 
Various specific and sensitive high performance pressure liquid chromatographic (HPLC) 
protocols have facilitated measuring metronidazole concentration in a variety of biological 
fluids such as plasma, serum, urine, gastric juice and saliva (Nilsson-Ehle et al., 1981, Mattila 
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et al., 1983, Jessa et al., 1996, Emami et al., 2006, Nikolin et al., 2004).   However, only a 
few studies have reported on metronidazole concentrations in vaginal secretions using this 
method (Davis et al., 1984; Larsen et al., 1986, Robertson et al. 1988).  These studies utilized 
various methods to collect vaginal secretions such as cotton swabs (Davis et al., 1984; Larsen 
et al., 1986) and sponges (Robertson et al. 1988). 
 
The aim of this part of the study is to describe the use of HPLC to measure the time-related 
secretion of metronidazole in the vaginal secretions of healthy female volunteers using a 
non-invasive specimen collection method. Concurrent determination of metronidazole in the 
serum was also undertaken. 
 
 




Six healthy female volunteers were recruited from the Nelson R Mandela School of Medicine, 
University of Kwazulu Natal.  These consenting volunteers were given a 2 g single dose of 
metronidazole orally.  Blood specimens were collected at 0, 1, 2, 4, and 8 hours after 
administration of metronidazole.  Vaginal specimens were collected immediately after blood 
collection at the same time points.  After recruitment one volunteer withdrew from the study 
as she was reluctant to provide blood specimens.  Therefore results are presented on 






5.2.2 Recovery of metronidazole from spiked tampon specimens using an agar       
            diffusion bioassay 
 
To measure the concentration of metronidazole in a spiked tampon specimen, a two-fold 
serial dilution of metronidazole was made with concentrations in the susceptibility range of 
the indicator organism.  Paper disks loaded with a standard volume of each of these dilutions 
as well as the fluid expressed from the tampon spiked with a known concentration of 
metronidazole were placed on the same agar plate seeded with the indicator organism and 
incubated under suitable conditions. 
 
A stock solution of 10 mg/ml metronidazole (Sigma- Aldrich, USA) was prepared (Appendix 
B).  This stock solution was serially diluted to obtain concentrations ranging from 256 to 32 
µg/ml. Sterile 9 mm paper disks were loaded with a 50 µl aliquot of each of these 
concentrations. 
 
To prepare the spiked tampon specimen, the stock solution was diluted to a final 
concentration of 320 µg/ml of metronidazole to which 5% foetal calf serum was added.  A 
vaginal tampon (Tampax® regular, Procter & Gamble, UK) was placed into 2 ml of the above 
solution in a 50 ml tube.  Once the solution was absorbed, the tampon was placed in a 30 ml 
sterile plastic screw–cap container (Sterilin, UK) containing a solution of 10 ml PBS (pH 7).  
After 1 hour, the tampon was thoroughly expressed using an autoclaved wooden tongue 
depressor (Sturm et al., 2002) and 50 µl of the expressed fluid was added to a sterile 9 mm 




Bacteroides fragilis (ATCC 25285) was used as the indictor organism.  This strain has a 
metronidazole MIC of 4 µg/ml and is able to form clearly defined inhibition zones at the 
concentrations used for construction of the standard curve.  Cultures of B. fragilis were grown 
and maintained on antibiotic free laked horse blood agar (Appendix D).  For the agar diffusion 
bioassay, a 0.5 McFarland suspension of the organism was evenly distributed on the surface 
of the laked horse blood agar plate in a Petri dish with a diameter of 90 mm, containing 20 ml 
of the culture medium.   
 
One disk each with the varying metronidazole concentrations (256 µg/ml, 128 µg/ml, 64 
µg/ml and 32 µg/ml) was placed onto the plate.  A paper disk containing 50 µl of the tampon 
fluid was placed in the centre of the plate.  The plates were incubated at 37°C for 48 hours 
under anaerobic conditions using the AnaeroGen atmosphere generation system (Thermo 
Scientific, USA).  This test was performed twice in triplicate.  Inhibition zones were read after 
48 hours of incubation.  The growth inhibition zone diameters (mm) were measured with a 
calliper. The test was done twice in triplicate. 
 
5.2.3 Measurement of metronidazole concentration in serum and vaginal secretions 
of volunteers using HPLC 
 
5.2.3.1 Specimen collection and processing 
 
Venous blood was collected from the volunteers before (time 0) and 1, 2, 4, and 8 hours after 
oral administration of 2 g of metronidazole.  The blood specimens were allowed to clot at 
room temperature (+ 25oC). The serum was separated from the clot by centrifugation in a 




At each time point, the volunteers were asked to insert a tampon (Tampax® regular, Procter 
& Gamble, UK) into the vagina immediately after collection of the blood specimens and to 
remove this after 15-20 minutes of insertion.  All volunteers were provided with verbal 
instructions to ensure correct tampon insertion and removal.  After removal, the tampon was 
placed in a 50 ml sterile plastic screw-cap container (Sterilin, UK) containing 10 ml of sterile 
distilled water.  This was immediately transported to the laboratory and the fluid was 
harvested as described above in 5.2.2.  The vaginal secretions obtained from the tampons 
were then evaporated to dryness by freeze-drying.  Specimens were stored at -20oC until use. 
 
5.2.3.2 High Performance Liquid Chromatography: Instrumentation and conditions 
 
Chromatography was performed with a Spectrochrom Series II (Spectrochrom, UK) single 
solvent delivery system connected to a variable wavelength Spectrochrom ultraviolet/visible 
(UV/VIS) detector.  The chromatography was performed by reverse phase separation at a 
flow rate of 2.0 ml/min. The UV/VIS absorbance detector was set at a wavelength of 315 nm, 
and 1.00 absorbance units.  Metronidazole standards and prepared specimens were manually 
injected via a rheodyne injector with a 10 µl column loop.  Chromatographic separation was 
performed on a RP 18, 55 µm Lichrospher 125 mm cartridge column.  (Merck, Germany). 
 
The polar mobile phase was a 70:30 mixture of methanol and potassium dihydrogen 
phosphate buffer (1.36 g/L).  To construct the standard curve, metronidazole (Sigma Aldrich, 
USA) was dissolved and serially diluted in this mobile phase mixture to produce 
concentrations of 5 mg, 2.5 mg, 1 mg, 0.5 mg and 0.25 mg metronidazole per 100 ml mobile 
phase mixture.  This enabled the calculation of the metronidazole content of vaginal and 
serum specimens using an external standard calibration graph. The working range of 
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standards was selected to target lower concentrations of metronidazole.  All reagents and 
solutions used were either analytical or HPLC grades. 
 
5.2.3.3 Specimen Preparation for HPLC 
 
The freeze-dried vaginal specimens were dissolved in 5 ml of mobile phase solvent.  The 
solution was then filtered through a nylon filter membrane (Sigma–Aldrich, USA) with a pore 
size of 0.45 µm and the filtrate was injected into the HPLC column. 
Preparation of the serum specimens was done based on the method published by Metz et al 
(2002) but modified as follows. After thawing, 1 ml of serum was mixed with 1 ml of cold 
methanol by vortexing for 20 s. The precipitate was allowed to settle for 10 min. The 
supernatant was filtered through a nylon filter membrane (Sigma-Aldrich, USA) with a pore 
size of 0.45 µm and the filtrate was injected into the HPLC column. 
 
 5.2.3.4  Data Analysis 
 
Area under the peak was calculated and stored by the Delta Chromatography data system 
(Digital Solutions Pty. Ltd, Australia).   The results were expressed as µg/ml concentrations 




5.3.1 Recovery of metronidazole from a spiked tampon specimen using agar 
diffusion bioassay 
 
Standard curves for metronidazole were generated by plotting inhibition zone diameter (mm) 
versus log of concentrations (µg/ml). The diameters of growth inhibition zones with 
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metronidazole reference solutions are shown in Table 5.1.  The standard curves (Figure 5.1), 
demonstrated good linearity in the 32 – 256 µg/ml range. 
 
Table 5.1:  Diameters of growth inhibition zones for metronidazole reference solutions obtained 
from agar diffusion bioassay tests (A and B) for standard curves 
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Figure 5.1:  Standard curves (Test A and Test B) of log10 concentration of metronidazole vs 
inhibition zone diameter 
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The representative linear equation for metronidazole was y = 0.0598x + 0.4266, in Test A and 
y = 0.0594x + 0.145 in Test B, where x is the zone diameter and y is the log10 of the 
concentration.  The inhibition zones produced by the test specimens are shown in Table 5.2.  
The average percentage recovery of metronidazole from the tampons spiked with 320 µg/ml 
metronidazole was 16.7%.  This recovery percentage was used to extrapolate the true vaginal 
concentrations in the volunteers from the measured concentrations. 
 
Table 5.2: Concentration (µg/ml) of metronidazole recovered from spiked tampon specimens 
 Specimen A  Specimen B 
Zone diameter (mm) 23 22 22  26.5 26 25.5 
Calculated log10 concentration (µg/ml) 
concentration  
1.80 1.74 1.74 1.72 1.69 1.66 
Calculated concentration (µg/ml) 63 55 55 52 49 46 
 
 
5.3.2 Measurement of metronidazole concentration in serum and vaginal secretions 
of volunteers using HPLC  
 
The representative linear equation for metronidazole was y =18225.5016x -32255.67, where x 
is the metronidazole concentration and y is the peak area.  The chromatograms and standard 
curve are shown in Appendix E.   
 
No interfering substances were observed in the baseline serum or vaginal specimens collected 
at 0 hours. Figure 5.2 (a-b) shows chromatograms of a vaginal specimen and serum specimen 
collected at 0 hours.  Figure 5.3 shows chromatograms of serum and vaginal specimens of 
volunteer C taken at 1, 2, 4 and 8 hours post administration of metronidazole.  None of the 
chromatograms had any interference at the retention time of 2.4 minutes, and the 
metronidazole peak eluted completely.  All chromatograms are shown in Appendix F.   
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            (a)                                                           (b) 
Figure 5.2: Chromatogram of a serum (a) and vaginal secretion (b) obtained from volunteer 
C after oral administration of metronidazole (2 g) at 0 hours.  
 
                   
         
   1h                                           2h                                         4h                                          8h 
(a) Serum  
 
 
               
   1h                                           2h                                         4h                                          8h 
(b) Vaginal secretion 
 
Figure 5.3: Chromatogram of serum (a) and vaginal secretions (b) obtained from volunteer C 
after oral administration of metronidazole (2 g) at 1, 2, 4 and 8 hours. 
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The 2 g single oral dose of metronidazole was well tolerated by all five volunteers.  Tables 5.3 
and 5.4 show the concentrations of metronidazole detected in both vaginal secretions and 
serum for each of the five volunteers.  The data show that all volunteers had a similar 




Table 5.3: Serum concentrations of metronidazole in 5 female volunteers after oral administration 
of 2 g of the drug 
 




Concentrations (µg/ml) in volunteer: 
 A B C D E Mean STDev* SEM** 
(±) 
0 0 0 0 0 0 - - - 
1 6.03 11.81 8.24 9.20 7.15 8.49 2.20 0.99 
2 6.99 10.83 13.85 14.34 9.68 11.14 3.04 1.36 
4 9.77 11.58 9.11 8.91 9.57 9.79 1.06 0.47 
8 7.87 7.63 4.12 7.00 2.97 5.92 2.23 1.00 
* Standard deviation 





Table 5.4: Vaginal concentrations of metronidazole in 5 female volunteers after oral 
administration of 2 g of the drug 
 
Time of specimen 
collection (hours) Concentrations (µg/ml) in volunteer: 
 A B C D E Mean STDev* SEM** 
(±) 
0 0 0 0 0 0 - - - 
1 0.91 0.74 0.88 0.53 0.67 0.75 0.16 0.07 
2 1.19 0.75 0.56 0.96 0.62 0.82 0.26 0.12 
4 0.61 0.52 0.47 1.11 1.05 0.75 0.30 0.14 
8 0.46 0.60 0.47 0.86 0.56 0.59 0.16 0.07 
* Standard deviation 





Maximum metronidazole concentrations in serum and vaginal secretions varied between 
volunteers between 1 and 8 hours after administration of the drug. The mean measured 
maximum value in serum was 11.14 µg/ml and 0.82 µg/ml in vaginal secretions. Table 5.5 
shows the extrapolated concentrations of metronidazole in vaginal secretions. The level of 
metronidazole in vaginal secretions varied between 44 and 60% of the amount present in 
serum (Figure 5.4) with a mean of 51%.   The extrapolated mean concentration at 2 hours post 
administration of the drug was 4.90 µg/ml. 
 






Volunteer: Mean STDev* SEM 
(±)** 
A B C D E 
1 5.46 4.44 5.28 3.18 4.02 4.48 0.94 0.42 
2 7.14 4.50 3.36 5.76 3.72 4.90 1.56 0.70 
4 3.66 3.12 2.82 6.66 6.30 4.51 1.83 0.82 
8 2.76 3.60 2.82 5.16 3.36 3.54 0.97 0.44 
Extrapolated metronidazole concentration (µg/ml) in vaginal secretions using a recovery factor of 6  
* Standard deviation 































Figure 5.4: Mean concentrations of metronidazole detected in serum (n = 5) and mean 
extrapolated concentrations in vaginal secretions (n = 5).  The bar represents the SEM (±) of 






The aim of this part of the study was to demonstrate the feasibility of using a vaginal tampon 
specimen collection method to determine levels of metronidazole in vaginal secretions using 
HPLC and to establish the vaginal secretion pattern of metronidazole in women without 
symptoms of genital tract infection.  Concurrent estimation of metronidazole in serum was 
also done to correlate levels of metronidazole absorption in the blood and secretion in the 
vagina. 
 
Information currently available on achievable metronidazole concentrations in vaginal 
secretions is limited.  Specimens used for determining metronidazole in the vagina by HPLC 
have been collected by sponges (Robertson et al., 1988) and swabs (Davis et al., 1984; Larsen 
et al. 1986) inserted in the vagina by a clinician.  Although these various methods of specimen 
collection resulted in detection of metronidazole, none of these may be practical to be applied 
to large clinical studies in which specimens need to be collected at time points after the 
clinical consultation.  Self-collection can happen at any time necessary for a study without the 
women reporting to a health care facility. 
 
We sought to explore the feasibility of using a self-administered-self-collected tampon for 
collection of vaginal secretions.  Given that tampons have a large surface area and are 
composed of highly absorbent material, substantial amounts of vaginal secretions from the 
mucosal surface, not limited to a specific area, may be collected using this method.  This high 
absorption capacity may also be a disadvantage as the tampon is able to retain a portion of the 
biological specimens collected even after processing. In addition, the tampon material may 
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bind an unknown percentage of the drug.  We demonstrated using an agar diffusion bioassay 
that approximately 83% of the metronidazole was retained in the tampon after processing.   
 
Several studies have described the use of self-administered tampons for specimen collection 
for diagnosis of STIs including T. vaginalis, as well as for bacterial vaginosis (Wilkinson et 
al., 1997; Tabrizi et al., 1998; Sturm et al., 2002).  Tampons were also successfully used to 
collect cervico-vaginal secretions for detection of endometrial cancer (Fiegl et al., 2004).  
Other studies used medicated tampons to assess the transvaginal absorption of tranexamic 
acid (Chien et al., 1982, Moodley et al., 1992).  Only one other study reported the use of 
tampons (Manthei et al., 1969 cited by Larsen et al., 1986), for collection of vaginal 
secretions to measure metronidazole concentrations. However highly sensitive methods for 
detection of metronidazole were not available during that time (Larsen et al., 1986).  Our 
study demonstrated that concentrations of metronidazole at the µg level could be detected in 
vaginal secretions obtained by self-collected tampons using HPLC. 
 
A modification of the method described by Metz et al (2002) was used for preparation of the 
serum specimen for HPLC analysis.  Due to the high protein concentration in serum, which 
would result in HPLC column degradation and plugging, these specimens could not be 
injected directly onto HPLC columns (Metz et al., 2002).  Therefore the serum specimen 
needed to be processed to remove most of the protein prior to injection into the HPLC 
column.  The cold methanol precipitation method and syringe filtration were essential 
techniques to remove substantial protein concentration (Metz et al., 2002).   
 
Apart from anti-protozoal activity, metronidazole and the other nitroimidazoles are potent 
drugs for the treatment and prophylaxis of infections with anaerobic bacteria. 
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Pharmacokinetic studies therefore focus on understanding the drug’s behaviour in blood and 
tissues and less on mucosal surfaces. Many studies reported on metronidazole concentrations 
in the serum after oral administration of the drug (Kane et al., 1961; Wood and Monro, 1975; 
Galmier et al., 1998).  These form the basis of the pharmacokinetic parameters of 
metronidazole as summarised in table 5.6.  We found median time to maximum concentration 
of metronidazole in serum to be 2 hours from administration of 2 g of the drug. This confirms 
that the time till peak concentration (Cmax) in blood in our study falls within these established 
parameters (Table 5.6).  The Cmax achieved with 2 g orally in our study is similar to that 
reported for a 500 mg dose.  Two of the three studies with comparable data report higher Cmax 
values while one study found levels similar to ours (Table 5.8).  This needs further 
elucidation.  
 
Table 5.6: Pharmacokinetic parameters of metronidazole 
Oral absorption > 90 % 
Cmax 500 mg oral 12 mg/ml after 20 min to 3 h 
Plasma half-life 6 - 11 h 
Volume of distribution 0.6 - 1.1 l/kg 
Plasma protein binding < 20 % 
                     Edwards, 2003 
 
Since trichomoniasis is mainly a non-invasive infection of the vagina, we tried to establish 
whether metronidazole levels achievable in vaginal secretions with the standard 2 g oral dose 
used for treatment of trichomoniasis was comparable with the MIC of T. vaginalis isolates in 
the majority of women responding to treatment. We found that the time of achievement of 
Cmax in vaginal secretions followed that in blood with peak levels between 1 and 4 hours.  




Table 5.7: Summary of clinical studies reporting metronidazole concentrations in blood 
















et al (1961) 
Polarographic 
method 
Not done 200mg orally for 
7 days 
1 h: 4.8 µg/ml 
2 h: 4.5 µg/ml 
4 h: 3.7 µg/ml 
8 h: 2.9 µg/ml 









Not done 2g orally 0.5 h: 35 µg/ml 
1 h: 40 µg/ml 
2 h: 39 µg/ml 
4 h: 38 µg/ml 
6 h: 32 µg/ml 
24 h: 5.7 µg/ml 
not done 











6h: 26.1 µg/ml 
12h: 12.6 µg/ml 
24h: 6.0 µg/ml 
48h: 0 µg/ml 
Larsen  
et al (1986) 
HPLC Cotton 
swab – 1 
minute 
contact 







(in 30 minutes) 
intravenously in 
7 patients 
2 h: 22.9 µg/ml 2h 11.1 µg/ml 
 
Robertson  
et al (1988) 











200mg orally at 
07, 15 
and 23 hours 
on days 1 and 2 
and then 800mg 
at the same 
times on days 3-
7. 
26h: 8.0 µg/ml 
 





A summary of clinical studies reporting metronidazole concentrations in blood and vaginal 
secretions is presented in Table 5.7.  It is impossible to draw conclusions from these 
studies since the study designs were different.  Table 5.8 provides a comparison between the 
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3 studies in which the metronidazole dose was 2 g and with time of measurement comparable 
to our study. This shows a wide variation between the reported concentrations. 
 
Table 5.8: Comparison of blood and vaginal concentrations 2 hours post administration of 2 g 
metronidazole p.o. 
 
Study Metronidazole (µg/ml) in: 
blood vaginal secretion 
Kane et al (1961) 4.5 not done 
Wood and Monro (1975) 39 not done 
Larsen et al (1986) 22.9 11.1 (48 %) 
This study 11.14 4.90 (44%) 
 
 
Like in our study, Kane et al (1961) also found in human volunteers maximum serum 
concentrations of metronidazole between 1 and 2 hours of administration of the drug, but at 
levels half of what we found.  This study used polarography in patients infected with T. 
vaginalis on a 200 mg dose of metronidazole three times daily for 7 days.  Robertson et al 
(1988) detected comparable concentrations of metronidazole in both plasma and vaginal 
content, using HPLC, in patients infected with T. vaginalis.  They used an intra-vaginal 
sponge to collect the secretions. This is comparable to collection by means of a tampon but 
the preparation of the specimen for HPLC differed. The higher level of vaginal secretion of 
the drug could be the result of inflammation of the vaginal wall. 
 
 
Another study also evaluated metronidazole concentration in vaginal secretions of patients on 
therapy (Larsen et al., 1986) and found, like us, that average vaginal levels were 
approximately half the serum concentration 2 hours after treatment.  They also reported that 
vaginal levels were comparable to serum levels 6 and 24 hours after treatment.  We deduced 
that concentrations in the vaginal secretions of healthy volunteers were approximately half of 
80 
 
the concentration in serum at all points of measurement up till 8 hours after the drug was 
administered (Figure 5.4).  The lowest concentration of the drug in both serum and vaginal 
secretions was observed at 8 hours after administration of the drug.   
 
 
Our findings need to be confirmed by means of a more extensive study in patients with 
trichomoniasis.  This study in healthy volunteers suggests that our approach can be used to 
investigate, in a non-invasive manner, whether impaired secretion of metronidazole into the 
vaginal compartment rather than resistance is the cause of failure to respond to standard 
metronidazole therapy.  Based on peak metronidazole absorption patterns observed in serum 
and vaginal specimens collected from healthy volunteers, it is recommended to measure levels 
approximately 2 hours after administration of the drug in studies in which metronidazole 
absorption is measured in patients.  The metronidazole secretion patterns may vary in infected 
individuals.  
 
The level of metronidazole detected in vaginal secretions should be directly related to the 
MIC breakpoint to be used to predict treatment outcome in infected individuals. Breakpoints 
currently in use vary from 4.3 to > 400 µg/ml. (Chapter 4, Table 4.10).  All but one of these 
breakpoints are higher than the maximum vaginal concentration observed in the study 
presented here. However, like the higher breakpoint values, this breakpoint (Upcroft and 
Upcroft, 2001a) does not differentiate between responders and non-responders to treatment 
(Chapter 4).  Of note, the maximum concentration of metronidazole detected in vaginal 
secretions was significantly higher (approximately 10 times) than the highest MIC in the 




To our knowledge, this is the second report of detection of metronidazole in vaginal 
secretions using a self-collected tampon specimen. However, the earlier study (Manthei et al., 
1969 cited by Larsen et al., 1986) was done > 40 years ago and before the application of 
sensitive detection methods such as gas liquid chromatography (GLC) or HPLC. Self-
collected vaginal tampon specimens evaluated for detection of metronidazole, using HPLC, 
was successful for the detection of µg levels of metronidazole concentration in vaginal 
secretions. The preliminary results presented here and the simplicity of this non-invasive 
specimen collection method and ease of processing suggests that this approach may be useful 
for investigation of the relationship between treatment failure and metronidazole absorption 
and vaginal secretion in females with trichomoniasis.  This method shows promise for 













Molecular typing methods using interspecies variation in the microbial genome to identify 
subtypes is a valuable tool to study the epidemiology of infectious diseases (Stiles et al., 2000).  
Differentiation of a microbial species into strains may contribute to studies of transmission 
dynamics.  Several molecular typing methods such as PCR-RFLP analysis of genomic DNA 
(Simões-Barbosa et al., 2005; Crucitti et al., 2008; Kock et al., 2013), RAPD techniques 
(Vanacova et al., 1997; Snipes et al., 2000, Kaul et al., 2004; Valadkhani et al., 2011; Rukasha 
et al., 2013), PFGE (Lehker and Alderete, 1999; Upcroft et al., 2006a; Upcroft et al., 2009), 
microsatellite genotyping (Prokopi et al., 2011, Conrad et al., 2011; Conrad et al., 2012; 
Conrad et al., 2013), and  MLST (Cornelius et al., 2012) have been used previously to 
differentiate T. vaginalis strains.  
 
The discriminatory power of molecular typing systems varies substantially. DNA-based 
techniques measure fixed, stable differences present in the genome (Stiles et al., 2000).  The 
PCR-RFLP method allows detection of point mutations within the sequences of PCR products 
(Crucitti et al., 2008). Mutations are detected by digestion with specific restriction 
endonucleases (Crucitti et al., 2008) followed by gel electrophoresis and staining with ethidium 
bromide.  PCR-RFLP based molecular methods for strain differentiation of T. vaginalis using 
various PCR target regions in the T. vaginalis genome have been reported (Stiles et al., 2000; 




One of the explanations for contradictory results of the metronidazole susceptibility test results 
and response to treatment (Chapter 4) is early reinfection, as reported for gonococcal disease 
(Moodley et al., 2002d).  To resolve this, a strain typing method for T. vaginalis is needed.  In 
an attempt to develop a genotypic typing method for use in an extension of the work presented 
here, we targeted a family of 650-bp repetitive sequences in the T. vaginalis genome, known as 
the Tv-E650 repeats (Paces et al., 1992).  These species-specific Tv-E650 repeats are well 
conserved in T. vaginalis (Paces et al., 1992).   PCR primers were developed to target a region 
within these repeats.  RFLP analysis of the PCR amplicons was thereafter performed in an 
attempt to discriminate between strains.     
 
 
6.2 MATERIALS AND METHODS 
 
6.2.1 Genomic DNA Isolation  
 
One hundred clinical isolates and the reference strain ATCC 50138 (IR 78) were used in this 
study. This included the 40 isolates used in the broth macro-dilution susceptibility testing 
(Chapter 4, section 4.2.1). The remaining 60 isolates were fresh isolates obtained from 
specimens collected from women attending the Africa Centre STI Reference Clinic at 
KwaMsane in the Hlabisa sub-district of KZN. All specimens were collected and processed as 
described in Chapter 3.  
 
A haemocytometer was used to count the number of T. vaginalis cells per ml (Appendix C) 
after which the culture was diluted to a final concentration of approximately 106 cells/ml.  
These cells were washed twice in phosphate-buffered saline (PBS), pH 7.4 using centrifugation 
at 1500 g for 10 min.  DNA was extracted from the cell pellets by the addition of 500 µl of lysis 
buffer followed by incubation at 65oC for 30 min (Shaio et al., 1997).   The lysis buffer was 
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freshly prepared from concentrated stock solutions to obtain final concentrations of 15 mM 
sodium citrate, 450 mM sodium chloride, 0.2% sodium dodecyl sulfate, and 100 µg of 
proteinase K per ml.  The DNA extracts were purified twice by adding equal volumes of 
phenol-chloroform (1:1; vol/vol) and once with chloroform only.  The aqueous phase was 
removed by pipetting and the DNA was precipitated with 2 volumes of 95% (vol/vol) ethanol 
and 0.1 volume of 3 M sodium acetate (pH 5.2).  The DNA pellet was washed with 70% 
(vol/vol) ethanol, air dried, and dissolved in 25 µl of TE buffer (10 mM Tris HCl [pH 7.6], 1 
mM EDTA). The preparation of all solutions used is described in Appendix G. 
 
6.2.2 Selection of PCR primers 
 
The two primers used in this study were designed using the published sequences of 650-bp 
DNA repeats cloned from the T. vaginalis genome (Paces et al., 1992).  One of the members of 
the repeat sequences, Tv-E650-1, was used to perform a nucleic acid similarity search against 
the T. vaginalis genome using the Blast 2.04 sequence similarity search software 
(Genbank, http://www.ncbi.nlm.nih.gov/genbank).  This yielded eight sequences that were 
conserved at the 5’ and 3’ ends (GenBank accession numbers: M86482 to M86489). These 
sequences were manually aligned and potential primer sets were identified.  The specificity of 
these primers was tested using the Amplify version 2.3 software (Department of Genetics, 
University of Wisconsin).   
 
For the PCR, a forward primer S1 (5’-TCCCGGATAATTGAAACGGA-3’) and a reverse 
primer S2 (5’-GAATGTGATAGCGAAATGGG-3’) were selected to amplify a region of 
approximately 413-bp within the 650-bp repeat region.  The primers were initially synthesized 
at the University of Cape Town and later by the University of Kwazulu Natal, Molecular 




6.2.3 PCR Amplification 
 
The PCR mixture contained 1 µl d NTPs (10 mM each of dATP, dCTP, dGTP, and dTTP), 20 
pmol of each primer, 1 µl template DNA (section 6.2.2), 5 µl of 10x PCR buffer, and 2.5 U 
AmpliTaq Gold Polymerase (Roche Molecular Systems, United States of America [USA]) in a 
total volume of 50 µl.  The following PCR conditions were used for 40 cycles: 94oC for 45s, 
50oC for 40s and 72oC for 1 minute.  Final extension consisted of one cycle at 72oC for 7 
minutes.  PCR amplifications were performed in a Perkin Elmer thermocycler model 9700 
(Perkin Elmer Applied Biosystems, USA).  With each amplification DNA extracted from the T. 
vaginalis reference strain ATCC 50138 was used as a positive control and distilled water as a 
negative control. 
 
6.2.4   Agarose gel electrophoresis 
 
Ten microliters of each of the PCR products was electrophoresed on a 1.5 % agarose gel 
(Appendix G) together with a DNA molecular weight marker XIV (100 base pair ladder) 
(Boehringer Mannheim Biochemica, Germany) in 1 X Tris/Borate/EDTA (TBE) buffer 
(Appendix G) at 80 V for 1 hour using a Hoefer PS 500XT DC power supply.  The gels were 
then stained with ethidium bromide (0.5 µg/ml) and viewed under ultraviolet illumination. 
 
6.2.5 RFLP analysis  
 
DNASIS software version 2.1 (Hitachi Software Engineering, Japan) was used to assist in the 
selection of suitable restriction enzymes. Acs1 (Boehringer Mannheim Biochemica, Germany) 
was selected due to the multiple cleavage sites of this enzyme within the amplicons and thus 
providing increased probability of discrimination. PCR products were digested according to the 
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manufacturer's instructions.  A volume of 10 µl of the amplicon solution was used for digestion.  
For the restriction with Acs1, the following components were added to an Eppendorf tube on 
ice in sequence to make up a total volume of 20µl: 7µl sterile distilled water, 2 µl restriction 
endonuclease buffer, 10 µl amplicon DNA, and 1 µl (10 units) Acs1 restriction enzyme. 
 
The components were mixed gently by pipetting, and centrifuged in a microcentrifuge at 12000 
x g for 5 seconds before incubating in a water bath for 3.5 hours at 56oC.  The reaction was 
terminated by transferring the tubes immediately on ice after adding 5 µl of gel loading buffer. 
Twenty microliters of each sample were electrophoresed on a 2 % agarose gel together with a 
DNA molecular weight marker XIV (100 base pair ladder) (Boehringer Mannheim 
Biochemica, Germany) in 1 X TBE buffer at 70 V for 1 hour 35 minutes using a Hoefer PS 
500XT DC power supply.  Restriction fragments were visualised as described above.  
 
6.2.6 Reproducibility and Discriminatory Value of the Typing Method 
 
Reproducibility and stability of the method was established by ensuring that the type strain 
ATCC 50138 was run as a control with each batch of isolates. The ATCC 50138 isolate was 
passaged multiple times in vitro and separate genomic DNA preparations were made prior to 
inclusion in each PCR run.   The discriminatory ability of the typing method was assessed by 
using Simpson’s Index of Diversity (Hunter and Gaston, 1988; Pillay et al., 1998), which 
calculates the probability that two unrelated isolates within a test population will have different 
types. A discriminatory value of 0 indicates that all the population members are identical and a 
value of 1 indicates that all the population members differ from one another.  The 







PCR on all clinical isolates as well as the reference strain ATCC 50138 produced amplicons of 





Figure 6.1: Results of the PCR. Lane 1: ATCC 50138; Lanes 2-10: T. vaginalis isolates (Lanes 2-
10), Lane 11: DNA Molecular Weight Marker XIV  
 
After restriction by means of Acs1 four patterns were obtained, designated type A to D (Figure 
6.2).  Only these four types were found among the 100 isolates (Appendix I).  The number of 
bands observed was 4 for type A, 5 for type B, 7 for type C and 6 for type D.  The size of the 
DNA fragments ranged from approximately 400-bp to 100-bp.  The type C pattern was 
predominant and was found in 47/100 isolates.  The reference strain also displayed the type C 
pattern.  Type B was found in 28/100, type D in 18/100, and type A in 7/100 isolates.  The 



















Figure 6.2: Acs1 RFLP patterns of the PCR amplicon.  The designated types of the RFLP patterns 
are indicated above the lanes. Lanes 1-17: ATCC 50138, KW1, KW2, KW3, STD1, KW4, KW5, 
KW6, KW7, CSW1, ATCC 50138, KW8, KW9, KW10, KW11, CSW2, DNA molecular weight 
marker XIV  
 
Table 6.1:  Distribution of PCR-RFLP Types (n = 100) 
TYPE Number (%) of T. vaginalis isolates  
 Africa Centre STI 
Reference Clinic* 
(Hlabisa sub-district) 
(n = 60)  
Female sex worker 
cohort** 
(uThukela district) 
(n = 31)  
STI Clinic, Prince Cyril Zulu 
Communicable Disease 
Centre*** (Durban)  
(n = 9) 
A 6 (10) 1 (3) 0 
B 14 (23) 11 (35) 3  
C 25 (42) 17 (55) 5  
D 15 (25) 2 (7) 1  
      The control strain ATCC 50138 was a Type C 
      *KW, **CSW, ***STD 
 
The PCR-RFLP pattern of the reference strain ATCC 50138 was stable and reproducible.   A 
discrimination index of 0.67 was obtained (Appendix I) using Simpson’s Index of Diversity 
(Hunter and Gaston, 1988).  
 
Table 6.2:  Distribution of MICs by genotypes by (n = 41) 
 
Genotype MIC (µg/ml) 
≤ 0.125 0.25 0.5 1 2 4 8 16 32 64 128 >128 
Type A 1            
Type B 12 2           
Type C 19 2 1         1* 
Type D 2 1           
*ATCC 50138  
   1      2      3      4      5        6       7       8       9    10     11     12     13     14     15     16    17 








Table 6.2 shows the distribution of the MICs of the 40 isolates used in the broth macro-dilution 
susceptibility testing (Chapter 4, section 4.2.1) according to genotypes.  The reference strain 
ATCC 50138 which had an MIC of >128 µg/ml was a type C.  There was no correlation 




Genotyping may contribute to the analysis of the relationship between metronidazole 
susceptibility test results and response to treatment.  In addition, molecular typing systems that 
determine trichomonal diversity could provide valuable insight into the global epidemiology of 
trichomoniasis.    
 
To be applicable as an epidemiological tool, a typing system needs to be stable and 
reproducible, to provide a typing result for all isolates within the species and to have sufficient 
discriminatory power.  The PCR-RFLP molecular typing methodology has been shown to 
provide stable and reproducible results with other organisms (Pillay et al., 1998) as well as with 
T. vaginalis (Crucitti et al., 2008).  We applied this technique as well. 
 
The discriminatory power of molecular typing systems in general varies substantially. For 
PCR-RFLP this depends on the choice of the nucleic acid target and restriction enzymes.  The 
target sequence for the PCR was chosen because the Tv-E650 repeats are well conserved in T. 
vaginalis strains from different geographical regions and is species-specific (Paces et al., 1992).  
Restriction of the PCR amplicons with Acs1 produced only 4 types, thus resulting in a moderate 
discrimination index of 0.67.  This indicates that if two T. vaginalis strains were randomly 
selected from a given population, then on 67% of occasions they would fall into different types. 
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A clonal purification step was not included and we were therefore unable to differentiate 
infections with mixed parasite lineages.  It may be possible that some patients were infected 
with more than one genotype.  Some of the genotype patterns observed could therefore be 
representative of a mixed infection.  On repeated typing, no changes were noted in the PCR 
products or RFLP pattern of the reference strain ATCC 50138, thus demonstrating both 
stability and reproducibility.  Nonetheless we cannot rule out the possibility that other strains 
may have been unstable.  This however does not impact on the fact that the methodology is 
moderately discriminative. 
 
The repeat region targeted in this study is well conserved and stable, and therefore may not be 
variable enough for strain differentiation of STI pathogens in populations with a high 
transmission rate.  In order to establish if isolates are epidemiologically related in short-term 
transmission studies it is important that target regions used for genotyping have adequate  
discriminatory power to differentiate among epidemiologically unrelated strains, and also 
display genetic variation that is stable enough to identify identical types from known sexual 
contacts (Viscidi et al., 2000).  This issue has been extensively discussed in studies 
describing strain typing of Neisseria gonorrhoeae (Viscidi et al., 2000; Moodley et al., 
2002d).   
 
Sixty of the 100 isolates were obtained from patients living in the same rural area. 
Trichomoniasis is endemic in this area with prevalence rates between 30-40% (Sturm et al., 
1998).  Therefore, one would expect a high genetic diversity due to frequent transmission of the 
organism.  Therefore clusters of strains would be expected within a background of strain 
diversity.  This has been shown to be the case for three other endemic STD pathogens e.g. N. 
gonorrhoeae from patients attending the same clinic in KwaMsane (Moodley et al, 2002d), as 
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well as Haemophilus ducreyi (Pillay et al., 1996) and Treponema pallidum (Pillay et al., 1998) 
isolates from the STI clinic at the Prince Cyril Zulu Centre for Communicable Diseases in 
Durban.  This highlights the limitations of the poor discriminatory capacity of the method 
applied for T. vaginalis in this study.  
 
Studies on the correlation between genotype and resistance show contradictory results. Over 
50% of our 40 isolates with low MICs (Chapter 4, section 4.2.1) had banding patterns that were 
identical to that of the metronidazole resistant reference strain ATCC 50138.  There was 
therefore no correlation between genotype and susceptibility testing.  A recent study conducted 
in South Africa also observed no correlation between metronidazole resistance and specific 
genetic clusters of 30 T. vaginalis isolates using a RAPD analysis method (Rukasha et al., 
2013).  Similarly, Rabiee and colleagues reported no correlation with resistance using a PCR 
method in 15 isolates (Rabiee et al., 2012).   Genotyping methods invariably use gene targets 
that are outside the regions that code for drug targets. Therefore, mutations in the genes used 
for genotyping usually do not correlate with mutations in genes coding for drug targets. This 
can only be expected if there is clonal spread of a resistant strain (Gandhi et al., 2014).   It was 
demonstrated using MLST and microsatellite genotyping that T. vaginalis has a two-type 
population structure (Cornelius et al., 2012; Conrad et al., 2012).  Conrad et al (2012) 
reported a correlation between metronidazole MICs and type 1 and type 2 isolates using 
microsatellite genotyping.  They demonstrated that a higher degree of metronidazole 
resistance was associated with the type 2 isolates (Conrad et al., 2012).  Conrad et al (2013) 
also successfully used microsatellite genotyping together with behavioural data, but not MICs, 
to differentiate treatment failure from reinfection in 42 repeat T. vaginalis infections in 
metronidazole–treated HIV positive women.  The reason for this finding could be due to an 




In conclusion, this chapter describes a genotyping system for T. vaginalis which has a 
moderate discriminatory power. This typing method has the ability to differentiate the 
population of trichomonads investigated in four genotypes. Application of more restriction 
endonucleases on the same amplicons could improve the system. The PCR-RFLP as 
described here has the potential to form the basis for more discriminative methodology by 
combining it with a second typing method with a different target region in the genome. Such 
an approach was shown to be successful with T. pallidum (Pillay et al., 1998).  Alternatively, 
a different genotyping method like MLST (Cornelius et al., 2012) or microsatellite combined 






SUMMARY AND DISCUSSION 
 
In Chapter 1, a motivation and outline of the study is provided.  For a meaningful 
interpretation of susceptibility testing of T. vaginalis, one needs to be able to measure 
susceptibility to the drugs used for treatment of trichomoniasis quantitatively, to be able to 
measure the concentration of drugs in the vaginal secretions of patients under treatment, to 
differentiate between treatment failure and early reinfection and to measure the 
contribution of other drugs given concomitantly in the context of syndromic management 
of vaginal discharge syndrome. The study presented in this thesis investigated 
methodologies that can contribute to answer these questions in one study cohort of 
patients. 
 
Chapter 2 provides a summary of the literature on the topic, focussing specifically on 
susceptibility testing of T. vaginalis to 5-nitroimidazoles, the mode of action and putative 
resistance mechanisms, strain typing and metronidazole pharmacokinetics.  
 
Chapter 3 describes the specimen collection method, transport from the clinical sites to 
the laboratory, the culture technique as well as the preparation of axenic stock cultures and 
their storage. 
 
In Chapter 4 two studies on susceptibility testing of T. vaginalis are presented.  In the first 
study, broth macro-dilution in Diamond’s TYM medium was applied.  We tested the effect 
of antibiotics (metronidazole, doxycycline, ciprofloxacin and ceftriaxone) which are 
recommended for use in the syndromic management of sexually transmitted diseases to 
establish whether added antimicrobial effect can be expected when used in combination 
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with metronidazole.  In addition, azithromycin and rifampicin were chosen for their 
potential activity against T vaginalis and fluconazole due to its frequent inclusion in 
treatment regimens for vaginal infections.  All 40 isolates tested were susceptible to 
metronidazole with MICs ranging from < 0.125 to 0.5 µg/ml.  Fluconazole and ceftriaxone 
demonstrated no in vitro activity.  Doxycycline had significant inhibitory effect with MICs 
ranging from 4 to 32 µg/ml.  Azithromycin, rifampicin and ciprofloxacin showed 
inhibitory effect but only at the highest concentrations used.  Those drugs that had 
inhibitory activity on T. vaginalis should be investigated further for synergistic effect with 
metronidazole. 
 
In the second study MICs of 160 clinical isolates were determined using the modified broth 
micro-dilution method described by Upcroft and Upcroft (2001a).  Classification of these 
160 isolates using the breakpoints suggested by Upcroft and Upcroft (2001a) showed 11% 
in vitro metronidazole resistance.  After 72 hours of incubation, MICs obtained under 
aerobic incubation ranged from 1.1 µg/ml to > 34.2 µg/ml (6.25 µM to > 200 µM) and 
from 0.3 µg/ml – > 17.1 µg/ml (1.6 µM to > 100 µM) under anaerobic incubation.  Only 
four isolates were resistant when incubated aerobically as well as anaerobically.  
 
In the 56 (43%) symptomatic patients that returned for follow-up no correlation between in 
vitro resistance and treatment outcome was found.  Some patients with isolates classified 
as susceptible failed to respond to treatment and vice versa.  Only one patient with an 
isolate classified as resistant was still culture positive on follow up and failed to respond 
clinically.  Why women infected with susceptible strains of T. vaginalis sometimes fail to 
respond to treatment clinically and microbiologically and why some improve clinically but 
remain infected with T. vaginalis following single dose metronidazole therapy remains 
unanswered but may possibly be due to the differences in vaginal secretion of 
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metronidazole between patients or to early reinfection.  An additional problem is the lack 
of uniformity with respect to methodology as well as breakpoints used for resistance. 
 
Chapter 5 describes the use of a self-administered and collected vaginal tampon specimen 
for measuring of metronidazole concentration in the vaginal secretions of five healthy 
volunteers, using HPLC.  Using an agar diffusion bioassay we demonstrated that there was a 
16.7% recovery of metronidazole from the spiked tampon after processing. It was 
subsequently extrapolated that the metronidazole concentration in vaginal secretions was 
approximately half the concentration present in serum at each time point.  Peak 
concentrations of metronidazole in serum and vaginal secretions were detected at two 
hours after oral administration of a 2 g single dose of the drug.   It is however important to 
recognize that due to inflammation of the tissues, the pharmacokinetics of metronidazole in 
women infected with T. vaginalis may differ.  
 
A typing method with high discriminatory power will be required to exclude early 
reinfection in cases of metronidazole treatment failure.  Chapter 6 describes a PCR-RFLP 
based genotyping method for characterization of T. vaginalis isolates.  The primers used 
were chosen from within a unique family of 650-bp DNA repeats cloned from the T. 
vaginalis genome (Paces et al., 1992).  Restriction of the PCR amplicons with restriction 
enzyme Acs1 differentiated 100 T. vaginalis isolates into four types.  This method resulted in 
a moderate discrimination index of 0.67.  This PCR-RFLP method did not have the ability to 
discriminate between resistant and susceptible isolates, but this may be on the account that 
metronidazole resistance in the population studied was not clonal. Better discriminatory 
power may be obtained if this PCR-RFLP method is combined with a second typing method 
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Diamond’s TYM Medium 
 
Trypticase (BBL)   20 g 
Yeast extract    10 g 
Maltose     5  g 
L-cysteine     1  g 
L-ascorbic acid    0.2 g 
Agar      0.5 g 
Distilled water   900 ml 
 
The medium was adjusted to a pH of 6.0 and autoclaved for 10 minutes.  The medium was 
then cooled to 48oC and 100 ml horse serum that had been inactivated at 65oC for 30 minutes 
was added.  Thereafter antibiotics were added: 1 g ampicillin, 100 µg/ml amikacin and 5 















ANTIBIOTIC STOCK SOLUTIONS 
 
1. Antibiotic stock solutions for broth macro-dilution  
 
A 10x concentration of each antibiotic was prepared as follows: 
Final concentration required:      128 µg/ml 
 
In 10 ml media:       128 µg/ml x 10 
         12800 µg/ml (10x) 
         Concentration required µg/ml 
         _______________________ 
       Purity µg/ml 
 
                                                         12800 µg/ml (x1000) 
         ___________________ 
If purity of antibiotic was 100%:               1000 µg/ml 
          
         12.8 mg/ml 
         128 mg/10 ml 
Antibiotic stock solution         0.128 g/10 ml 
 
 
2. Metronidazole stock solution for agar diffusion bioassay 
 
Preparation of 10 mg/ml metronidazole stock solution: 
 
0.1 g metronidazole (Sigma-Aldrich, USA) was dissolved in 500 µl acetic acid and made up 








Calculation of cell concentration using the haemocytometer 
 
A 1:1 dilution of the cell suspension was prepared by adding 10 µl of cell suspension to 10 
µl of 0.4% trypan blue solution (Sigma-Aldrich, USA).  Trypan blue differentiates between 
dead and viable cells.  Viable cells appear colourless and dead cells stain blue.   
Approximately 10 µl of this dilution was added to one of the chambers of the 
haemocytometer.  The cells were viewed under a microscope at 100x magnification.  The 
full grid on the haemocytometer contains a total of 9 squares, each of which is 1 mm2.   
The cells were counted on 4 of these 1 mm2 squares, and the average number of cells was 
calculated.     
 
The cell concentration was calculated from the following formula: 
 
Total cells/ml = Total cells counted x dilution factor x 10, 000 cells/ml 
        # of Squares 
 
 
To determine the number of cells present in the original sample, the cell concentration was 












Laked Horse Blood Agar 
 
Trypticase peptone   23 g 
Glucose    1 g 
Yeast extract    2 g 
Sodium chloride   5 g 
Hemin (1% solution)   10 ml 
Vitamin K (1% solution) 1ml 
L-cystine    0.5 g 
Agar     15 g 
Horse blood (laked)   45.5 ml 
Distilled water   1000 ml 
 
The powders were weighed and dissolved in 1000 ml distilled water.  This solution was 
autoclaved at 121oC for 15 minutes. The solution was then cooled to 56oC.  Hemin (1% 
solution), vitamin K (1% solution) and horse blood was added. The medium was then 




































2. Metronidazole standard curve 
 
Table 1: Average peak areas for metronidazole working standard range 
Metronidazole concentration 
(µg/ml)  























y = 18225.5016x-32255.67 
 









1. HPLC chromatograms of biological specimens 
 




























































































































































































2. Concentration of metronidazole in biological specimens 
 
 










A - 1 h 48756.4 52760.3 50758.35 4.555 0.9110 
A - 2 h 75007.6 77857.8 76432.70 5.964 1.1928 
A - 4 h 21286.1 25105.2 23195.65 3.043 0.6086 
A - 8 h 9046.0 9894.2 9470.10 2.289 0.4578 
      
B - 1 h 35121.4 35197.1 35159.25 3.699 0.7398 
B - 2 h 37820.1 34378.3 36099.20 3.750 0.7500 
B - 4 h 15471.5 14212.5 14842.00 2.584 0.5168 
B - 8 h 24743.3 20541.8 22642.55 3.012 0.6024 
      
C - 1 h 46813.5 49838.2 48325.85 4.421 0.8842 
C - 2 h 19611.4 18711.8 19161.60 2.821 0.5642 
C - 4 h 8025.8 12926.7 10476.25 2.345 0.4690 
C - 8 h 8812.4 11465 10138.70 2.326 0.4652 
      
D - 1 h 13531.1 18425.6 15978.35 2.6470 0.5294 
D - 2 h 55858.2 53739.5 54798.85 4.776 0.9552 
D - 4 h 61624.1 76742.6 69183.35 5.566 1.1132 
D - 8 h 46527.3 45530.2 46028.75 4.295 0.8590 
      
E - 1 h 30341.1 26602.8 28471.95 3.332 0.6664 
E - 2 h 25604.4 22580.9 24092.65 3.092 0.6184 
E - 4 h 64668.1 61986 63327.05 5.244 1.0488 
E - 8 h 17810.9 19082.7 18446.80 2.7820 0.5564 










Table 3: Peak areas and metronidazole concentration (µg/ml) in serum specimens 
Volunteer/specimen 
collection time 
Area 1 Area 2 Average Metronidazole 
concentration 
(µg/ml) 
A - 1 h 40954.0 42216.7 41585.35 6.025 
A - 2 h 93013.6 97299.8 95156.70 6.991 
A - 4 h 145222.1 146396.3 145809.20 9.770 
A - 8 h 111208.2 110965.7 111086.95 7.865 
     
B - 1 h 181434.2 184426.9 182930.55 11.807 
B - 2 h 165070.9 166829.0 165949.95 10.827 
B - 4 h 178835.6 188978.8 183907.20 11.582 
B - 8 h 106762.9 107613.7 107188.30 7.628 
     
C - 1 h 117463.0 118520.5 117991.75 8.244 
C - 2 h 215559.8 224803.4 220181.60 13.851 
C - 4 h 132740.7 134930.0 133835.35 9.113 
C - 8 h 41602.0 44193.0 42897.5 4.124 
     
D - 1 h 139138.0 131621.7 135379.85 9.198 
D - 2 h 233206.4 224843.2 229024.80 14.336 
D - 4 h 127416.3 132955.0 130185.65 8.913 
D - 8 h 94381.6 96265.5 95323.55 7.000 
     
E - 1 h 98237.9 97922.2 98080.05 7.151 
E - 2 h 141489.0 146877.5 144183.25 9.681 
E - 4 h 138692.7 145771.5 142232.10 9.5740 















DNA isolation and gel electrophoresis solutions 
 
1. Phosphate-Buffered Saline (PBS),  pH 7.4 
     NaCl     8 g 
    KCl      0.2 g 
     Na2HPO4    1.44 g 
    KH2PO4    0.24 g 
     Distilled water   800 ml 
     
The solution was adjusted to a pH of 7.4 using I M HCl, made up to a volume of 1 L 
and autoclaved.  
 
2. TSE, pH 8 
     Tris-HCl (20 mM)    1.58 g 
     NaCl (100 mM)    2.92 g 
    EDTA (50 mM)    9.36 g 
 
 The solution was adjusted to a pH of 8 with 1 M NaOH and autoclaved.   
 
3. Proteinase K (20 mg/ml) 
20 mg proteinase K (Boehringer Mannheim, Germany) was dissolved in 1 ml sterile     






4.    Rnase A (10 mg/ml) 
       Sodium acetate  0.01 M 
              Distilled water  15 ml 
 
0.027 g of sodium acetate was dissolved in 15 ml distilled water, the pH was 
adjusted to 5.2, and the volume was made up to 20 ml with distilled water. 
 
10 mg Rnase A (Boehringer Mannheim, Germany) was dissolved in 1 ml sodium 
acetate.  The enzyme preparation was heated to 100oC for 15 minutes and allowed to 
cool slowly to room temperature.  50 µl volumes were aliquoted into Eppendorf 
tubes and stored at –20oC. 
 
 5. 1 M Sodium citrate 
     Sodium citrate    147.05 g 
     Distilled water  500 ml 
 
 Dissolve and autoclave. 
 
6. 1M Tris-HCl, pH 7.6 
        Tris base     24.22 g 
        Distilled water    160 ml 
 
   pH was adjusted to 7.6 with approximately 12 ml of concentrated hydrochloric acid.  
   The volume was adjusted to 200 ml, dispensed and autoclaved.     




7.   10 mM TE Buffer, pH 7.6 
      Tris-HCl, pH 7.6    5 ml 
         EDTA     0.1861 g 
         Distilled water    300 ml 
 
The EDTA was dissolved and the pH was adjusted to 7.6, using 1 M HCL. The 
volume was adjusted to 500 ml and autoclaved for 20 minutes. 
 
8. 5x TBE, pH 8.5 
         Tris base     54 g 
         Boric acid     27.5 g 
         0.5 M EDTA, pH 8    20 ml 
   
 The solution was adjusted to a pH of 8.5, made up to a volume of 1 L and autoclaved.   
  
9. Ethidium bromide (10 mg/ml) 
   Add 1 g of ethidium bromide (Sigma-Aldrich, USA) to 100 ml of sterile distilled     
   water.  Stir on a magnetic stirrer for several hours until the dye has dissolved.  The    
   container containing the ethidium bromide was wrapped in aluminium foil and  
   stored at room  temperature. 
 
10. Gel loading buffer 
    Glycerol    50g 
    Tris-HCL ph7.5   5 ml of 1M Tris HCL, ph7.5 
    EDTA    1ml of 500 mM EDTA 
    Bromophenol blue   0.05 g 
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    RNase    300 µl of 10 mg/ml 
    Distilled water   to 100 ml 
    
   Boil for 15 minutes at 100oC.  Cool overnight at room temperature.  Dispense into    
   Eppendorf tubes and store at -20oC.  
 
11.   Agarose gel 
   Agarose was added to 0.5x TBE buffer and dissolved by heating in a microwave.  
Ethidium bromide (0.5 µg/ml) (Sigma-Aldrich, USA) was added to the solution 
after cooling to 50oC. This agarose solution was poured into a gel mould and, a gel 
comb was placed at one end of the gel.  The agarose was allowed to set for 30-45 
minutes at room temperature before removing the comb. The gel was then 

















Simpson’s Index of Diversity (Hunter and Gaston, 1988) 
 
Simpson’s Index of Diversity, D, was calculated as follows: 
             s 
D = 1-         1       Σ nj (nj – 1) 
N (N-1)    j = 1 
  
 
Where s is the number of types; nj is the number of strains falling into the j type and N is the size 
of the sample population.  This statistic gives the probability that two randomly selected strains 
will belong to different types.  A value of D = 0 would indicate that all the population members 
are identical and D = 1 would indicate that all the population members differ from one another. 
 
Calculation:   Sample size: 100   Strain distribution:   Type A = 7 
                          No of types: 4   Type B = 28 
   Type C = 47 
                                                                                    Type D = 18 
                              
                                                                  
Index of diversity 
N = 100 
S = 4 
 
D = 1- 1 (7X6+28X27+47X46+18X17) 
          100 X 99  

















Figure 2: Acs1 PCR-RFLP patterns of the PCR amplicon. Lanes 1-15: ATCC 50138, KW12, 
STD2, KW13, STD3, CSW3, blank, uncut PCR amplicon, STD4, KW14, CSW4, KW15, KW16, 






   
Figure 3: Acs1 PCR-RFLP patterns of the PCR amplicon. Lanes 1-7: KW17, CSW6, STD5, 
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Figure 4: Acs1 PCR-RFLP patterns of the PCR amplicon. Lanes 1-11: ATCC 50138, KW19, 




Figure 5: Acs1 PCR-RFLP patterns of the PCR amplicon. Lanes 1-14: KW24, KW25, CSW9, 
KW26, KW27, KW28, uncut PCR amplicon, CSW10, KW29, CSW11, CSW12, CSW13, ATCC 





Figure 6: Acs1 PCR-RFLP patterns of the PCR amplicon. Lanes 1-20: ATCC 50138, KW30, 
KW31, KW32, CSW14, KW33, CSW15, KW34, KW35, KW36, CSW16, CSW17, KW37, 
KW38, CSW18, CSW19, CSW20, KW39, KW40, DNA molecular weight marker XIV 
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Figure 7: Acs1 PCR-RFLP patterns of the PCR amplicon. Lanes 1-19:, ATCC 50138, KW41, 
KW42, KW43, uncut PCR amplicon, KW44, CWS21, CWS22, KW45, KW46, KW47, uncut 







Figure 8: Acs1 PCR-RFLP patterns of the PCR amplicon. Lanes 1-18:, KW50, CSW27, KW51, 
KW52, KW53, CSW28, KW54, KW55, KW56, CSW29, CSW30, KW57, KW58, CSW31, 
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